Abstract
Retinitis pigmentosa (RP) is a syndromic diagnosis used to describe a large group of genetically heterogeneous inherited retinal degenerations (IRDs) characterized by a bilateral, slowly progressive pigmentary retinopathy typically associated with nyctalopia, midperipheral and peripheral progressive visual field defects, and eventual loss of central vision. The condition can be isolated to the retina or be associated with systemic abnormalities (i.e., sensorineural hearing loss, neurologic and metabolic defects) in the context of specific syndromes. In this chapter, RP and allied conditions are discussed with regard to clinical presentation, clinical findings, inheritance and genetic basis, and management.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pruett RC. Retinitis pigmentosa: clinical observations and correlations. Trans Am Ophthalmol Soc. 1983;81:693–735.
Donders FC. Beitrage zur patlhologischen Anatomie des Auiges. 2. Pigmnentbildung in der Netzhauit. Arch Ophthalmol. 1857;3:139–65.
Liebreich R. Abktunift aus Eheni unter Blutsverwandten als Grund von Retinitis pigmentosa. Deutsch Klin. 1861;13:53–5.
Fahim AT, Daiger SP, Weleber RG. Nonsyndromic retinitis pigmentosa overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K, et al., editors. GeneReviews((R)). Seattle: University of Washington; 1993.
Dryja TP, Berson EL. Retinitis pigmentosa and allied diseases. Implications of genetic heterogeneity. Invest Ophthalmol Vis Sci. 1995;36(7):1197–200.
Massof RW, Finkelstein D. Two forms of autosomal dominant primary retinitis pigmentosa. Doc Ophthalmol. 1981;51(4):289–346.
Gonin J. Le scotome annulaire dans la degenerescence pigmentaire de la retine. Ann d’Ocul. 1901;125:101–30.
Grover S, Fishman GA, Brown J Jr. Patterns of visual field progression in patients with retinitis pigmentosa. Ophthalmology. 1998;105(6):1069–75.
Foxman S, Heckenlively J, Bateman J, Wirtschafter J. Classification of congenital and early onset retinitis pigmentosa. Arch Ophthalmol. 1985;103:1502–6.
Matsui R, McGuigan Iii DB, Gruzensky ML, Aleman TS, Schwartz SB, Sumaroka A, et al. SPATA7: evolving phenotype from cone-rod dystrophy to retinitis pigmentosa. Ophthalmic Genet. 2016;37(3):333–8.
Boughman J, Conneally P, Nance W. Population genetic studies of retinitis pigmentosa. Am J Hum Genet. 1980;32:223–34.
Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of retinitis pigmentosa in Maine. Am J Ophthalmol. 1984;97:357–65.
Alexander KR, Derlacki DJ, Fishman GA. Coherence and the judgment of spatial displacements in retinitis pigmentosa. Vis Res. 1999;39(13):2267–74.
Alexander KR, Derlacki DJ, Fishman GA. Visual acuity vs letter contrast sensitivity in retinitis pigmentosa. Vis Res. 1995;35(10):1495–9.
Alexander KR, Derlacki DJ, Xie W, Fishman GA, Szlyk JP. Discrimination of spatial displacements by patients with retinitis pigmentosa. Vis Res. 1998;38(8):1171–81.
Alexander KR, Hutman LP, Fishman GA. Abnormal foveal spectral sensitivity in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1987;28(4):725–30.
Alexander KR, Hutman LP, Fishman GA. Dark-adapted foveal thresholds and visual acuity in retinitis pigmentosa. Arch Ophthalmol. 1986;104(3):390–4.
Sieving PA, Fishman GA. Refractive errors of retinitis pigmentosa patients. Br J Ophthalmol. 1978;62(3):163–7.
Berson EL, Rosner B, Simonoff E. Risk factors for genetic typing and detection in retinitis pigmentosa. Am J Ophthalmol. 1980;89(6):763–75.
Hendriks M, Verhoeven VJM, Buitendijk GHS, Polling JR, Meester-Smoor MA, Hofman A, et al. Development of refractive errors-what can we learn from inherited retinal dystrophies? Am J Ophthalmol. 2017;182:81–9.
Heckenlively J. The frequency of posterior subcapsular cataract in the hereditary retinal degenerations. Am J Ophthalmol. 1982;93(6):733–8.
Fishman GA, Anderson RJ, Lourenco P. Prevalence of posterior subcapsular lens opacities in patients with retinitis pigmentosa. Br J Ophthalmol. 1985;69(4):263–6.
Newsome DA, Michels RG. Detection of lymphocytes in the vitreous gel of patients with retinitis pigmentosa. Am J Ophthalmol. 1988;105(6):596–602.
Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, et al. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013;120(1):100–5.
Pruett RC. Retinitis pigmentosa. A biomicroscopical study of vitreous abnormalities. Arch Ophthalmol. 1975;93(8):603–8.
Pruett RC, Albert DM. Vitreous degeneration in myopia and retinitis pigmentosa. Bull Soc Belge Ophtalmol. 1987;223(Pt 1):211–28.
Hajali M, Fishman GA, Anderson RJ. The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol. 2008;92(8):1065–8.
Hajali M, Fishman GA. The prevalence of cystoid macular oedema on optical coherence tomography in retinitis pigmentosa patients without cystic changes on fundus examination. Eye (Lond). 2009;23(4):915–9.
Walia S, Fishman GA, Hajali M. Prevalence of cystic macular lesions in patients with Usher II syndrome. Eye (Lond). 2009;23(5):1206–9.
Strong S, Liew G, Michaelides M. Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention. Br J Ophthalmol. 2017;101(1):31–7.
Huckfeldt RM, Comander J. Management of cystoid macular edema in retinitis pigmentosa. Semin Ophthalmol. 2017;32(1):43–51.
Strong SA, Hirji N, Quartilho A, Kalitzeos A, Michaelides M. Retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors. Br J Ophthalmol. 2019;103(2):233–7.
Marano F, Deutman AF, Leys A, Aandekerk AL. Hereditary retinal dystrophies and choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2000;238(9):760–4.
Battaglia Parodi M, Iacono P, Bandello F. Antivascular endothelial growth factor in hereditary dystrophies. Dev Ophthalmol. 2010;46:107–10.
Khan JA, Ide CH, Strickland MP. Coats’-type retinitis pigmentosa. Surv Ophthalmol. 1988;32(5):317–32.
den Hollander AI, Heckenlively JR, van den Born LI, de Kok YJ, van der Velde-Visser SD, Kellner U, et al. Leber congenital amaurosis and retinitis pigmentosa with coats-like exudative vasculopathy are associated with mutations in the crumbs homologue 1 (CRB1) gene. Am J Hum Genet. 2001;69(1):198–203.
Shields CL, Kaliki S, Al-Dahmash S, Rojanaporn D, Shukla SY, Reilly B, et al. Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases. JAMA Ophthalmol. 2013;131(3):328–34.
Patil L, Lotery AJ. Coat’s-like exudation in rhodopsin retinitis pigmentosa: successful treatment with an intravitreal dexamethasone implant. Eye. 2014;28(4):449–51.
Goodman G, Gunkel RD. Familial electroretinographic and adaptometric studies in retinitis pigmentosa. Am J Ophthalmol. 1958;46(3 Part 2):142–72; discussion 72–8
Gouras P, Carr RE. Electrophysiological studies in early retinitis pigmentosa. Arch Ophthalmol. 1964;72:104–10.
Berson EL, Gouras P, Gunkel RD. Rod responses in retinitis pigmentosa, dominantly inherited. Arch Ophthalmol. 1968;80(1):58–67.
Berson EL, Gouras P, Gunkel RD, Myrianthopoulos NC. Dominant retinitis pigmentosa with reduced penetrance. Arch Ophthalmol. 1969;81(2):226–34.
Berson EL. Retinitis pigmentosa and allied diseases: applications of electroretinographic testing. Int Ophthalmol. 1981;4(1–2):7–22.
Berson EL, Gouras P, Hoff M. Temporal aspects of the electroretinogram. Arch Ophthalmol. 1969;81(2):207–14.
Birch DG, Hood DC, Nusinowitz S, Pepperberg DR. Abnormal activation and inactivation mechanisms of rod transduction in patients with autosomal dominant retinitis pigmentosa and the pro-23-his mutation. Invest Ophthalmol Vis Sci. 1995;36:1603–14.
Birch DG, Sandberg MA. Dependence of cone b-wave implicit time on rod amplitude in retinitis pigmentosa. Vis Res. 1987;27(7):1105–12.
Sandberg MA, Berson EL, Effron M. Rod-cone interaction in the distal human retina. Science. 1981;212(4496):829–31.
Frishman LJ, Sieving PA, Steinberg RH. Contributions to the electroretinogram of currents originating in proximal retina. Vis Neurosci. 1988;1(3):307–15.
Aleman TS, Soumittra N, Cideciyan AV, Sumaroka AM, Ramprasad VL, Herrera W, et al. CERKL mutations cause an autosomal recessive cone-rod dystrophy with inner retinopathy. Invest Ophthalmol Vis Sci. 2009;50(12):5944–54.
Audo I, Robson AG, Holder GE, Moore AT. The negative ERG: clinical phenotypes and disease mechanisms of inner retinal dysfunction. Surv Ophthalmol. 2008;53(1):16–40.
Milam AH, Li ZY, Cideciyan AV, Jacobson SG. Clinicopathologic effects of the Q64ter rhodopsin mutation in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1996;37(5):753–65.
Renner AB, Kellner U, Cropp E, Foerster MH. Dysfunction of transmission in the inner retina: incidence and clinical causes of negative electroretinogram. Graefes Arch Clin Exp Ophthalmol. 2006;244(11):1467–73.
Weleber RG, Watzke RC, Shults WT, Trzupek KM, Heckenlively JR, Egan RA, et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol. 2005;139(5):780–94.
Birch DG. Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: an overview. Mol Genet Metab. 1999;66(4):356–66.
Weleber RG, Gupta N, Trzupek KM, Wepner MS, Kurz DE, Milam AH. Electroretinographic and clinicopathologic correlations of retinal dysfunction in infantile neuronal ceroid lipofuscinosis (infantile Batten disease). Mol Genet Metab. 2004;83(1–2):128–37.
Weleber RG. The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses. Eye (Lond). 1998;12(Pt 3b):580–90.
Aleman TS, Lam BL, Cideciyan AV, Sumaroka A, Windsor EA, Roman AJ, et al. Genetic heterogeneity in autosomal dominant retinitis pigmentosa with low-frequency damped electroretinographic wavelets. Eye (Lond). 2009;23(1):230–3.
Azari AA, Aleman TS, Cideciyan AV, Schwartz SB, Windsor EAM, Sumaroka A, et al. Retinal disease expression in Bardet-Biedl syndrome-1 (BBS1) is a spectrum from maculopathy to retina-wide degeneration. Invest Ophthalmol Vis Sci. 2006;47(11):5004–10.
Lam BL, Liu M, Hamasaki DI. Low-frequency damped electroretinographic wavelets in young asymptomatic patients with dominant retinitis pigmentosa: a new electroretinographic finding. Ophthalmology. 1999;106(6):1109–13.
Aleman T, LaVail M, Montemayor R, Ying G-S, Maguire M, Laties A, et al. Augmented rod bipolar cell function in partial receptor loss: an ERG study in P23H rhodopsin transgenic and normal rats. Vis Res. 2001;41:2779–97.
Collison FT, Fishman GA, Nagasaki T, Zernant J, McAnany JJ, Park JC, et al. Characteristic ocular features in cases of autosomal recessive PROM1 cone-rod dystrophy. Invest Ophthalmol Vis Sci. 2019;60(6):2347–56.
Berson EL, Simonoff EA. Dominant retinitis pigmentosa with reduced penetrance. Further studies of the electroretinogram. Arch Ophthalmol. 1979;97(7):1286–91.
Berson EL. Electroretinographic findings in retinitis pigmentosa. Jpn J Ophthalmol. 1987;31(3):327–48.
Berson EL. Retinitis pigmentosa. The Friedenwald lecture. Invest Ophthalmol Vis Sci. 1993;34(5):1659–76.
Berson EL, Sandberg MA, Rosner B, Birch DG, Hanson AH. Natural course of retinitis pigmentosa over a 3-year interval. Am J Ophthalmol. 1985;99:240–51.
Andreasson SO, Sandberg MA, Berson EL. Narrow-band filtering for monitoring low-amplitude cone electroretinograms in retinitis pigmentosa. Am J Ophthalmol. 1988;105(5):500–3.
Berson EL. Long-term visual prognoses in patients with retinitis pigmentosa: the Ludwig von Sallmann lecture. Exp Eye Res. 2007;85(1):7–14.
Birch DG, Anderson JL. Rod visual fields in cone-rod degeneration. Comparisons to retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1990;31(11):2288–99.
Birch DG, Anderson JL, Fish GE. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod dystrophy. Ophthalmology. 1999;106(2):258–68.
Grover S, Fishman GA, Anderson RJ, Alexander KR, Derlacki DJ. Rate of visual field loss in retinitis pigmentosa. Ophthalmology. 1997;104(3):460–5.
Sandberg MA, Rosner B, Weigel-DiFranco C, McGee TL, Dryja TP, Berson EL. Disease course in patients with autosomal recessive retinitis pigmentosa due to the USH2A gene. Invest Ophthalmol Vis Sci. 2008;49(12):5532.
Massof RW, Finkelstein D. Vision threshold profiles in sector retinitis pigmentosa. Arch Ophthalmol. 1979;97(10):1899–904.
Sandberg MA, Weigel-DiFranco C, Rosner B, Berson EL. The relationship between visual field size and electroretinogram amplitude in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1996;37(8):1693–8.
Massof RW, Finkelstein D. Rod sensitivity relative to cone sensitivity in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1979;18(3):263–72.
Massof RW, Finkelstein D, Starr SJ, Kenyon KR, Fleischman JA, Maumenee IH. Bilateral symmetry of vision disorders in typical retinitis pigmentosa. Br J Ophthalmol. 1979;63(2):90–6.
Massof RW, Johnson MA, Finkelstein D. Peripheral absolute threshold spectral sensitivity in retinitis pigmentosa. Br J Ophthalmol. 1981;65(2):112–21.
Massof RW, Wu L, Finkelstein D, Perry C, Starr SJ, Johnson MA. Properties of electroretinographic intensity-response functions in retinitis pigmentosa. Doc Ophthalmol. 1984;57(3):279–96.
Kemp CM, Jacobson SG, Faulkner DJ. Two types of visual dysfunction in autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1988;29(8):1235–41.
Massof RW, Dagnelie G, Benzschawel T, Palmer RW, Finkel Stein D. First order dynamics of visual field loss in retinitis pigmentosa. Clin Vis Sci. 1990;5(1):1–26.
Grover S, Fishman GA, Anderson RJ, Lindeman M. A longitudinal study of visual function in carriers of X-linked recessive retinitis pigmentosa. Ophthalmology. 2000;107(2):386–96.
Sandberg MA, Rosner B, Weigel-DiFranco C, Dryja TP, Berson EL. Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations. Invest Ophthalmol Vis Sci. 2007;48(3):1298–304.
Birch DG, Bennett LD, Duncan JL, Weleber RG, Pennesi ME. Long-term follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants. Am J Ophthalmol. 2016;170:10–4.
Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, et al. Effect of oral valproic acid vs placebo for vision loss in patients with autosomal dominant retinitis pigmentosa: a randomized phase 2 multicenter placebo-controlled clinical trial. JAMA Ophthalmol. 2018;136(8):849–56.
Birch DG, Fish GE. Rod ERGs in children with hereditary retinal degeneration. J Pediatr Ophthalmol Strabismus. 1986;23(5):227–32.
Birch DG, Herman WK, deFaller JM, Disbrow DT, Birch EE. The relationship between rod perimetric thresholds and full-field rod ERGs in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1987;28(6):954–65.
Birch DG, Hood DC, Locke KG, Hoffman DR, Tzekov RT. Quantitative electroretinogram measures of phototransduction in cone and rod photoreceptors: normal aging, progression with disease, and test-retest variability. Arch Ophthalmol. 2002;120(8):1045–51.
Cideciyan AV, Jacobson SG. An alternative phototransduction model for human rod and cone ERG a-waves: normal parameters and variation with age. Vis Res. 1996;36:2609–21.
Huang Y, Cideciyan AV, Papastergiou GI, Banin E, Semple-Rowland SL, Milam AH, et al. Relation of optical coherence tomography to microanatomy in normal and rd chickens. Invest Ophthalmol Vis Sci. 1998;39(12):2405–16.
Banin E, Cideciyan AV, Aleman TS, Petters RM, Wong F, Milam AH, et al. Retinal rod photoreceptor-specific gene mutation perturbs cone pathway development. Neuron. 1999;23(3):549–57.
Cideciyan A, Aleman T, Bennett J, Banin E, editors. Comparative study of mammalian phototransduction in vivo: a prelude to preclinical treatment trials in retinal degenerations: Vision Science and Its Applications Optical Society of America; 1999.
Fishman GA, Jacobson SG, Alexander KR, Cideciyan AV, Birch DG, Weleber RG, et al. Outcome measures and their application in clinical trials for retinal degenerative diseases: outline, review, and perspective. Retina. 2005;25(6):772–7.
Aleman TS, Cideciyan AV, Sumaroka A, Schwartz SB, Roman AJ, Windsor EA, et al. Inner retinal abnormalities in X-linked retinitis pigmentosa with RPGR mutations. Invest Ophthalmol Vis Sci. 2007;48(10):4759–65.
Aleman TS, Cideciyan AV, Sumaroka A, Windsor EAM, Herrera W, White DA, et al. Retinal laminar architecture in human retinitis pigmentosa caused by rhodopsin gene mutations. Invest Ophthalmol Vis Sci. 2008;49(4):1580–90.
Cideciyan AV, Swider M, Aleman TS, Roman MI, Sumaroka A, Schwartz SB, et al. Reduced-illuminance autofluorescence imaging in ABCA4-associated retinal degenerations. J Opt Soc Am A Opt Image Sci Vis. 2007;24(5):1457–67.
Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res. 2010;29(5):398–427.
Cideciyan AV, Swider M, Aleman TS, Feuer WJ, Schwartz SB, Russell RC, et al. Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. Invest Ophthalmol Vis Sci. 2012;53(2):841–52.
Cideciyan AV, Swider M, Jacobson SG. Autofluorescence imaging with near-infrared excitation:normalization by reflectance to reduce signal from choroidal fluorophores. Invest Ophthalmol Vis Sci. 2015;56(5):3393–406.
Jacobson SG, Cideciyan AV, Sumaroka A, Roman AJ, Charng J, Lu M, et al. Outcome measures for clinical trials of Leber congenital amaurosis caused by the intronic mutation in the CEP290 gene. Invest Ophthalmol Vis Sci. 2017;58(5):2609–22.
Aleman TS, Uyhazi KE, Serrano LW, Vasireddy V, Bowman SJ, Ammar MJ, et al. RDH12 mutations cause a severe retinal degeneration with relatively spared rod function. Invest Ophthalmol Vis Sci. 2018;59(12):5225–36.
Sieving PA, Niffenegger JH, Berson EL. Electroretinographic findings in selected pedigrees with choroideremia. Am J Ophthalmol. 1986;101(3):361–7.
Birch DG, Locke KG, Felius J, Klein M, Wheaton DK, Hoffman DR, et al. Rates of decline in regions of the visual field defined by frequency-domain optical coherence tomography in patients with RPGR-mediated X-linked retinitis pigmentosa. Ophthalmology. 2015;122(4):833–9.
Lazow MA, Hood DC, Ramachandran R, Burke TR, Wang YZ, Greenstein VC, et al. Transition zones between healthy and diseased retina in choroideremia (CHM) and Stargardt disease (STGD) as compared to retinitis pigmentosa (RP). Invest Ophthalmol Vis Sci. 2011;52(13):9581–90.
Jacobson SG, Sumaroka A, Aleman TS, Cideciyan AV, Danciger M, Farber DB. Evidence for retinal remodelling in retinitis pigmentosa caused by PDE6B mutation. Br J Ophthalmol. 2007;91(5):699–701.
Jones BW, Watt CB, Marc RE. Retinal remodelling. Clin Exp Optom. 2005;88(5):282–91.
Trichonas G, Traboulsi EI, Ehlers JP. Correlation of ultra-widefield fundus autofluorescence patterns with the underlying genotype in retinal dystrophies and retinitis pigmentosa. Ophthalmic Genet. 2017;38(4):320–4.
Trichonas G, Traboulsi EI, Ehlers JP. Ultra-widefield fundus autofluorescence patterns in retinitis pigmentosa and other retinal dystrophies. Ophthalmic Genet. 2017;38(1):98–100.
Andersen KM, Sauer L, Gensure RH, Hammer M, Bernstein PS. Characterization of retinitis pigmentosa using fluorescence lifetime imaging ophthalmoscopy (FLIO). Transl Vis Sci Technol. 2018;7(3):20.
Fakin A, Sustar M, Brecelj J, Bonnet C, Petit C, Zupan A, et al. Double hyperautofluorescent rings in patients with USH2A-retinopathy. Genes (Basel). 2019;10(12):956.
Robson AG, Michaelides M, Luong VA, Holder GE, Bird AC, Webster AR, et al. Functional correlates of fundus autofluorescence abnormalities in patients with RPGR or RIMS1 mutations causing cone or cone rod dystrophy. Br J Ophthalmol. 2008;92(1):95–102.
Robson AG, Michaelides M, Saihan Z, Bird AC, Webster AR, Moore AT, et al. Functional characteristics of patients with retinal dystrophy that manifest abnormal parafoveal annuli of high density fundus autofluorescence; a review and update. Doc Ophthalmol. 2008;116(2):79–89.
Sengillo JD, Lee W, Nagasaki T, Schuerch K, Yannuzzi LA, Freund KB, et al. A distinct phenotype of eyes shut homolog (EYS)-retinitis pigmentosa is associated with variants near the C-terminus. Am J Ophthalmol. 2018;190:99–112.
Tee JJL, Kalitzeos A, Webster AR, Peto T, Michaelides M. Quantitative analysis of hyperautofluorescent rings to characterize the natural history and progression in Rpgr-associated retinopathy. Retina. 2018;38(12):2401–14.
Bietto GB. Su alcune torme atipiche o rare di degenerazione retinica (degenerazione tappetoretiniche e quadri morbosi similari). Boll Oculist. 1937;16:1159–244.
Haase WH, K.A. Uber familiare bilaterale sektorenformige retinopathia pigmentosa. Klin Monatsbl Augenheilkd. 1965;147:365–75.
Fledelius H, Simonsen SE. A family with bilateral symmetrical sectoral pigmentary retinal lesion. Acta Ophthalmol. 1970;48(1):14–22.
Sugita T, Kondo M, Piao C-H, Ito Y, Terasaki H. Correlation between macular volume and focal macular electroretinogram in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2008;49(8):3551.
Hood DC, Lin CE, Lazow MA, Locke KG, Zhang X, Birch DG. Thickness of receptor and post-receptor retinal layers in patients with retinitis pigmentosa measured with frequency-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2009;50(5):2328.
Lima LH, Cella W, Greenstein VC, Wang N-K, Busuioc M, Smith RT, et al. Structural assessment of hyperautofluorescent ring in patients with retinitis pigmentosa. Retina. 2009;29(7):1025–31.
Bird AC. Clinical investigation of retinitis pigmentosa. Aust N Z J Ophthalmol. 1988;16(3):189–98.
Jacobson S, Cideciyan A, Iannaccone A, Weleber R, Fishman G, Maguire A, et al. Disease expression of RP1 mutations causing autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2000;41(7):1898–908.
Holopigian K, Seiple W, Greenstein VC, Hood DC, Carr RE. Local cone and rod system function in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2001;42(3):779–88.
Apushkin MA, Fishman GA, Alexander KR, Shahidi M. Retinal thickness and visual thresholds measured in patients with retinitis pigmentosa. Retina. 2007;27(3):349–57.
Jacobson SG, Roman AJ, Aleman TS, Sumaroka A, Herrera W, Windsor EAM, et al. Normal central retinal function and structure preserved in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2010;51(2):1079–85.
Branson SV, McClintic JI, Stamper TH, Haldeman-Englert CR, John VJ. Sector retinitis pigmentosa associated with novel compound heterozygous mutations of CDH23. Ophthalmic Surg Lasers Imaging Retina. 2016;47(2):183–6.
Cideciyan AV, Hood DC, Huang Y, Banin E, Li ZY, Stone EM, et al. Disease sequence from mutant rhodopsin allele to rod and cone photoreceptor degeneration in man. Proc Natl Acad Sci U S A. 1998;95(12):7103–8.
Jacobson SG, McGuigan DB 3rd, Sumaroka A, Roman AJ, Gruzensky ML, Sheplock R, et al. Complexity of the class B phenotype in autosomal dominant retinitis pigmentosa due to rhodopsin mutations. Invest Ophthalmol Vis Sci. 2016;57(11):4847–58.
Milam AH, De Castro EB, Smith JE, Tang W-X, John SK, Gorin MB, et al. Concentric retinitis pigmentosa: clinicopathologic correlations. Exp Eye Res. 2001;73(4):493–508.
Pinckers A, Greydanus J, Deutman AF, Duinkerke-Eerola KU. Atypical sector pigmentary dystrophy. Int Ophthalmol. 1986;9(2–3):143–9.
To KW, Adamian M, Jakobiec FA, Berson EL. Clinical and histopathologic findings in clumped pigmentary retinal degeneration. Arch Ophthalmol. 1996;114(8):950–5.
Davidson AE, Millar ID, Urquhart JE, Burgess-Mullan R, Shweikh Y, Parry N, et al. Missense mutations in a retinal pigment epithelium protein, bestrophin-1, cause retinitis pigmentosa. Am J Hum Genet. 2009;85(5):581–92.
Yardley J, Leroy BP, Hart-Holden N, Lafaut BA, Loeys B, Messiaen LM, et al. Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). Invest Ophthalmol Vis Sci. 2004;45(10):3683–9.
Pearlman JT, Saxton J, Hoffman G. Unilateral retinitis pigmentosa sine pigmento. Br J Ophthalmol. 1976;60(5):354–60.
Errera MH, Robson AG, Wong T, Hykin PG, Pal B, Sagoo MS, et al. Unilateral pigmentary retinopathy: a retrospective case series. Acta Ophthalmol. 2019;97(4):e601–e17.
Takahashi VKL, Takiuti JT, Jauregui R, Mahajan VB, Tsang SH. Rates of bone spicule pigment appearance in patients with retinitis pigmentosa sine pigmento. Am J Ophthalmol. 2018;195:176–80.
Sandberg MA, Gaudio AR, Berson EL. Disease course of patients with pericentral retinitis pigmentosa. Am J Ophthalmol. 2005;140(1):100–6.
Francois J, De Rouck A. ERG and EOG in pericentral pigmentary retinopathy. Vis Res. 1971;11(10):1216.
Francois J, De Rouck A, Cambie E, De Laey JJ. Visual functions in pericentral and central pigmentary retinopathy. Ophthalmologica. 1972;165(1):38–61.
Szamier RB, Berson EL. Histopathologic study of an unusual form of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1982;22(5):559–70.
Hayasaka S, Fukuda K, Tsuchiya M, Mizuno K. Pericentral pigmentary retinal degeneration. Jpn J Ophthalmol. 1985;29(2):161–9.
Hayasaka S, Ugomori S, Kanamori M, Setogawa T. Pericentral retinal degeneration deteriorates during pregnancies. Ophthalmologica. 1990;200(2):72–6.
Grondahl J. Pericentral retinal dystrophy. Acta Ophthalmol. 1987;65(3):344–51.
Traboulsi EI, O’Neill JF, Maumenee IH. Autosomal recessive pericentral pigmentary retinopathy. Am J Ophthalmol. 1988;106(5):551–6.
Bass SJ, Noble KG. Autosomal dominant pericentral retinochoroidal atrophy. Retina. 2006;26(1):71–9.
Noble KG. Peripapillary (pericentral) pigmentary retinal degeneration. Am J Ophthalmol. 1989;108(6):686–90.
Durlu YK, Burumcek E, Devranoglu K, Mudun AB, Karacorlu S, Arslan MO. Associated ocular findings in pericentral pigmentary retinopathy. Acta Ophthalmol Scand. 1997;75(1):101–3.
Comander J, Weigel-DiFranco C, Maher M, Place E, Wan A, Harper S, et al. The genetic basis of pericentral retinitis pigmentosa-a form of mild retinitis pigmentosa. Genes (Basel). 2017;8(10):256.
Selmer KK, Grondahl J, Riise R, Brandal K, Braaten O, Bragadottir R, et al. Autosomal dominant pericentral retinal dystrophy caused by a novel missense mutation in the TOPORS gene. Acta Ophthalmol. 2010;88(3):323–8.
Matsui R, Cideciyan AV, Schwartz SB, Sumaroka A, Roman AJ, Swider M, et al. Molecular heterogeneity within the clinical diagnosis of pericentral retinal degeneration. Invest Ophthalmol Vis Sci. 2015;56(10):6007.
Curcio CA, Sloan KR, Kalina RE, Hendrickson AE. Human photoreceptor topography. J Comp Neurol. 1990;292(4):497–523.
Lenis TL, Klufas MA, Randhawa S, Sharma M, Sarraf D. Posterior polar annular choroidal dystrophy: a case series. Retin Cases Brief Rep. 2017;11(Suppl 1):S24–S7.
Del Valle-Nava F, Sanchez-Ramos J, Hernandez-Vazquez A, Gonzalez-Saldivar G, Ramirez-Estudillo A. Posterior polar annular choroidal dystrophy association with cystoid macular edema. Clin Case Rep. 2019;7(2):389–90.
Forte R, Aptel F, Feldmann A, Chiquet C. Multimodal imaging of posterior polar annular choroidal dystrophy. Retin Cases Brief Rep. 2018;12(1):29–32.
Ghodasra DH, Besirli C. Posterior polar annular choroidal dystrophy. JAMA Ophthalmol. 2015;133(12):e152148.
Stokkermans TJ, Trichonas G. Chloroquine and hydroxychloroquine toxicity. Treasure Island: StatPearls; 2019.
Bellmann C, Neveu MM, Scholl HP, Hogg CR, Rath PP, Jenkins S, et al. Localized retinal electrophysiological and fundus autofluorescence imaging abnormalities in maternal inherited diabetes and deafness. Invest Ophthalmol Vis Sci. 2004;45(7):2355–60.
Choi JY, Sandberg MA, Berson EL. Natural course of ocular function in pigmented paravenous retinochoroidal atrophy. Am J Ophthalmol. 2006;141(4):763–5.
Mukhopadhyay R, Holder GE, Moore AT, Webster AR. Unilateral retinitis pigmentosa occurring in an individual with a germline mutation in the RP1 gene. Arch Ophthalmol. 2011;129(7):954–6.
Cideciyan AV, Jacobson SG. Image analysis of the tapetal-like reflex in carriers of X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1994;35(11):3812–24.
Falls HF, Cotterman CW. Chorioretinal degeneration. A sex-linked form in which heterozygous women exhibit a tapetal-like retinal reflex. Arch Ophthalmol. 1948;40(6):685–703.
Acton JH, Greenberg JP, Greenstein VC, Marsiglia M, Tabacaru M, Theodore Smith R, et al. Evaluation of multimodal imaging in carriers of X-linked retinitis pigmentosa. Exp Eye Res. 2013;113:41–8.
Weleber RG, Butler NS, Murphey WH, Sheffield VC, Stone EM. X-linked retinitis pigmentosa associated with a 2-base pair insertion in codon 99 of the RP3 gene RPGR. Arch Ophthalmol. 1997;115(11):1429–35.
Berendschot TT, DeLint PJ, van Norren D. Origin of tapetal-like reflexes in carriers of X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1996;37(13):2716–23.
Berson EL, Rosen JB, Simonoff EA. Electroretinographic testing as an aid in detection of carriers of X-chromosome-linked retinitis pigmentosa. Am J Ophthalmol. 1979;87(4):460–8.
Fishman GA, Weinberg AB, McMahon TT. X-linked recessive retinitis pigmentosa. Clinical characteristics of carriers. Arch Ophthalmol. 1986;104(9):1329–35.
Kalitzeos A, Samra R, Kasilian M, Tee JJL, Strampe M, Langlo C, et al. Cellular imaging of the Tapetal-like reflex in carriers of Rpgr-associated retinopathy. Retina. 2019;39(3):570–80.
Alexander KR, Barnes CS, Fishman GA. ON-pathway dysfunction and timing properties of the flicker ERG in carriers of X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2003;44(9):4017–25.
Jacobson SG, Yagasaki K, Feuer WJ, Roman AJ. Interocular asymmetry of visual function in heterozygotes of X-linked retinitis pigmentosa. Exp Eye Res. 1989;48(5):679–91.
Genead MA, Fishman GA, Lindeman M. Structural and functional characteristics in carriers of X-linked retinitis pigmentosa with a tapetal-like reflex. Retina. 2010;30(10):1726–33.
Shifera AS, Kay CN. Early-onset X-linked retinitis pigmentosa in a heterozygous female harboring an intronic donor splice site mutation in the retinitis pigmentosa GTPase regulator gene. Ophthalmic Genet. 2015;36(3):251–6.
Leber T. Uber retinitis pigmentosa and Angeborne amaurose. Albrecht von Graefes Arch Klin Ophthalmol. 1869;15:1–25.
Heher K, Traboulsi E, Maumenee I. The natural history of Leber’s congenital amaurosis. Ophthalmology. 1992;99:241–5.
den Hollander AI, Lopez I, Yzer S, Zonneveld MN, Janssen IM, Strom TM, et al. Identification of novel mutations in patients with Leber congenital amaurosis and juvenile RP by genome-wide homozygosity mapping with SNP microarrays. Invest Ophthalmol Vis Sci. 2007;48(12):5690–8.
Kaplan J. Leber congenital amaurosis: from darkness to spotlight. Ophthalmic Genet. 2008;29(3):92–8.
den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res. 2008;27(4):391–419.
Kumaran N, Moore AT, Weleber RG, Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. Br J Ophthalmol. 2017;101(9):1147–54.
Pasadhika S, Fishman GA, Stone EM, Lindeman M, Zelkha R, Lopez I, et al. Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2010;51(5):2608–14.
Hebrard M, Manes G, Bocquet B, Meunier I, Coustes-Chazalette D, Herald E, et al. Combining gene mapping and phenotype assessment for fast mutation finding in non-consanguineous autosomal recessive retinitis pigmentosa families. Eur J Hum Genet. 2011;19(12):1256–63.
Walia S, Fishman GA, Jacobson SG, Aleman TS, Koenekoop RK, Traboulsi EI, et al. Visual acuity in patients with Leber’s congenital amaurosis and early childhood-onset retinitis pigmentosa. Ophthalmology. 2010;117(6):1190–8.
Weleber RG. Infantile and childhood retinal blindness: a molecular perspective (the Franceschetti lecture). Ophthalmic Genet. 2002;23(2):71–97.
Aboshiha J, Dubis AM, van der Spuy J, Nishiguchi KM, Cheeseman EW, Ayuso C, et al. Preserved outer retina in AIPL1 Leber’s congenital amaurosis: implications for gene therapy. Ophthalmology. 2015;122(4):862–4.
Jacobson SG, Cideciyan AV, Aleman TS, Sumaroka A, Roman AJ, Swider M, et al. Human retinal disease from AIPL1 gene mutations: foveal cone loss with minimal macular photoreceptors and rod function remaining. Invest Ophthalmol Vis Sci. 2011;52(1):70–9.
Chiang P-W, Wang J, Chen Y, Fu Q, Zhong J, Chen Y, et al. Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. Nat Genet. 2012;44(9):972–4.
Falk MJ, Zhang Q, Nakamaru-Ogiso E, Kannabiran C, Fonseca-Kelly Z, Chakarova C, et al. NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet. 2012;44(9):1040–5.
Koenekoop RK, Wang H, Majewski J, Wang X, Lopez I, Ren H, et al. Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. Nat Genet. 2012;44(9):1035–9.
Perrault I, Hanein S, Zanlonghi X, Serre V, Nicouleau M, Defoort-Delhemmes S, et al. Mutations in nmnat1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. Nat Genet. 2012;44(9):975–7.
Kaplan J, Perrault I, Hanein S, Dollfus H, Rozet J-M. Mutations in NMNAT1 cause Leber congenital amaurosis with severe macular and optic atrophy. Med Sci (Paris). 2013;29(1):26–7.
Vincent A, AlAli A, MacDonald H, VandenHoven C, Héon E. Specific retinal phenotype in early IQCB1-related disease. Eye. 2017;32:646.
Cideciyan AV, Aleman TS, Jacobson SG, Khanna H, Sumaroka A, Aguirre GK, et al. Centrosomal-ciliary gene CEP290/NPHP6 mutations result in blindness with unexpected sparing of photoreceptors and visual brain: implications for therapy of Leber congenital amaurosis. Hum Mutat. 2007;28(11):1074–83.
Cideciyan AV, Rachel RA, Aleman TS, Swider M, Schwartz SB, Sumaroka A, et al. Cone photoreceptors are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy. Hum Mol Genet. 2011;20(7):1411–23.
Aleman TS, Cideciyan AV, Aguirre GK, Huang WC, Mullins CL, Roman AJ, et al. Human CRB1-associated retinal degeneration: comparison with the rd8 Crb1-mutant mouse model. Invest Ophthalmol Vis Sci. 2011;52:6898.
Jacobson SG, Cideciyan AV, Aleman TS, Pianta MJ, Sumaroka A, Schwartz SB, et al. Crumbs homolog 1 (CRB1) mutations result in a thick human retina with abnormal lamination. Hum Mol Genet. 2003;12(9):1073–8.
Perrault I, Rozet J, Calvas P, Gerber S, Camuzat A, Dollfus H, et al. Retinal-specific guanylate cyclase gene mutations in Leber’s congenital amaurosis. Nat Genet. 1996;14(4):461–4.
Morimura H, Fishman GA, Grover S, Fulton A, Berson E, Dryja T. Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or Leber congenital amaurosis. PNAS. 1998;95:3088–93.
Perrault I, Delphin N, Hanein S, Gerber S, Dufier JL, Roche O, et al. Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype. Hum Mutat. 2007;28(4):416.
Collison FT, Park JC, Fishman GA, McAnany JJ, Stone EM. Full-field pupillary light responses, luminance thresholds, and light discomfort thresholds in CEP290 Leber congenital Amaurosis patients. Invest Ophthalmol Vis Sci. 2015;56(12):7130–6.
Sheck L, WIL D, Moradi P, Robson AG, Kumaran N, Liasis AC, et al. Leber congenital amaurosis associated with mutations in CEP290, clinical phenotype, and natural history in preparation for trials of novel therapies. Ophthalmology. 2018;125(6):894–903.
Sumaroka A, Garafalo AV, Semenov EP, Sheplock R, Krishnan AK, Roman AJ, et al. Treatment potential for macular cone vision in Leber congenital amaurosis due to CEP290 or NPHP5 mutations: predictions from artificial intelligence. Invest Ophthalmol Vis Sci. 2019;60(7):2551–62.
Cideciyan AV, Jacobson SG, Drack AV, Ho AC, Charng J, Garafalo AV, et al. Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect. Nat Med. 2019;25(2):225–8.
Booij JC, Florijn RJ, ten Brink JB, Loves W, Meire F, van Schooneveld MJ, et al. Identification of mutations in the AIPL1, CRB1, GUCY2D, RPE65, and RPGRIP1 genes in patients with juvenile retinitis pigmentosa. J Med Genet. 2005;42(11):e67.
Sharon D, Wimberg H, Kinarty Y, Koch K-W. Genotype-functional-phenotype correlations in photoreceptor guanylate cyclase (GC-E) encoded by GUCY2D. Prog Retin Eye Res. 2018;63:69–91.
Jacobson S, Aleman T, Cideciyan A, Sumaroka A, Schwartz S, Windsor E, et al. Identifying photoreceptors in blind eyes due to RPE65 mutations: prerequisite for human gene therapy success. Proc Natl Acad Sci. 2005;102:6177–82.
Jacobson SG, Cideciyan AV, Aleman TS, Sumaroka A, Schwartz SB, Roman AJ, et al. Leber’s congenital amaurosis caused by an RPGRIP1 mutation shows treatment potential. Ophthalmology. 2007;114:895.
Jacobson SG, Cideciyan AV, Aleman TS, Sumaroka A, Schwartz SB, Windsor EA, et al. RDH12 and RPE65, visual cycle genes causing Leber congenital amaurosis, differ in disease expression. Invest Ophthalmol Vis Sci. 2007;48(1):332–8.
Jacobson SG, Cideciyan AV, Aleman TS, Sumaroka A, Windsor EA, Schwartz SB, et al. Photoreceptor layer topography in children with Leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci. 2008;49(10):4573–7.
Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Clinical perspective: treating RPE65-associated retinal dystrophy. Mol Ther. 2020. https://doi.org/10.1016/j.ymthe.2020.11.029. Online ahead of print.
Deng Y, Huang H, Wang Y, Liu Z, Li N, Chen Y, et al. A novel missense NMNAT1 mutation identified in a consanguineous family with Leber congenital amaurosis by targeted next generation sequencing. Gene. 2015;569(1):104–8.
Eblimit A, Zaneveld SA, Liu W, Thomas K, Wang K, Li Y, et al. NMNAT1 E257K variant, associated with Leber congenital amaurosis (LCA9), causes a mild retinal degeneration phenotype. Exp Eye Res. 2018;173:32–43.
Finding of Rare Disease Genes Canada C, Koenekoop RK, Wang H, Majewski J, Wang X, Lopez I, et al. Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. Nat Genet. 2012;44(9):1035–9.
Han IC, Critser DB, Stone EM. Swept-source OCT of a macular Coloboma in NMNAT1-Leber congenital amaurosis. Ophthalmol Retina. 2018;2(10):1040.
Kumaran N, Robson AG, Michaelides M. A novel case series of Nmnat1-associated early-onset retinal dystrophy: extending the phenotypic spectrum. Retin Cases Brief Rep. 2018.
Nash BM, Symes R, Goel H, Dinger ME, Bennetts B, Grigg JR, et al. NMNAT1 variants cause cone and cone-rod dystrophy. Eur J Hum Genet. 2018;26(3):428–33.
Pennesi ME, Stover NB, Stone EM, Chiang P-W, Weleber RG. Residual electroretinograms in young Leber congenital amaurosis patients with mutations of AIPL1. Invest Ophthalmol Vis Sci. 2011;52(11):8166.
Tan MH, Smith AJ, Pawlyk B, Xu X, Liu X, Bainbridge JB, et al. Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors. Hum Mol Genet. 2009;18(12):2099–114.
Ahmad A, Daud S, Kakar N, Nurnberg G, Nurnberg P, Babar ME, et al. Identification of a novel LCA5 mutation in a Pakistani family with Leber congenital amaurosis and cataracts. Mol Vis. 2011;17:1940–5.
Corton M, Avila-Fernandez A, Vallespín E, López-Molina MI, Almoguera B, Martín-Garrido E, et al. Involvement of LCA5 in Leber congenital amaurosis and retinitis pigmentosa in the Spanish population. Ophthalmology. 2014;121(1):399–407.
den Hollander AI, Koenekoop RK, Mohamed MD, Arts HH, Boldt K, Towns KV, et al. Mutations in LCA5, encoding the ciliary protein lebercilin, cause Leber congenital amaurosis. Nat Genet. 2007;39(7):889–95.
Mackay DS, Borman AD, Sui R, van den Born LI, Berson EL, Ocaka LA, et al. Screening of a large cohort of Leber congenital amaurosis and retinitis pigmentosa patients identifies novel LCA5 mutations and new genotype-phenotype correlations. Hum Mutat. 2013;34(11):1537–46.
Song JY, Aravand P, Nikonov S, Leo L, Lyubarsky A, Bennicelli JL, et al. Amelioration of neurosensory structure and function in animal and cellular models of a congenital blindness. Mol Ther. 2018;26(6):1581–93.
Bedoukian EC, Zhu X, Serrano LW, Scoles D, Aleman TS. Nmnat1-associated cone-rod dystrophy: evidence for a spectrum of Foveal Maldevelopment. Retin Cases Brief Rep. 2020.
Berson EL, Gouras P, Gunkel RD. Progressive cone-rod degeneration. Arch Ophthalmol. 1968;80(1):68–76.
Gill JS, Georgiou M, Kalitzeos A, Moore AT, Michaelides M. Progressive cone and cone-rod dystrophies: clinical features, molecular genetics and prospects for therapy. Br J Ophthalmol. 2019;103(5):711–20.
Yagasaki K, Jacobson SG. Cone-rod dystrophy. Phenotypic diversity by retinal function testing. Arch Ophthalmol. 1989;107(5):701–8.
Szlyk JP, Fishman GA, Alexander KR, Peachey NS, Derlacki DJ. Clinical subtypes of cone-rod dystrophy. Arch Ophthalmol. 1993;111(6):781–8.
Thiadens AA, Phan TM, Zekveld-Vroon RC, Leroy BP, van den Born LI, Hoyng CB, et al. Clinical course, genetic etiology, and visual outcome in cone and cone-rod dystrophy. Ophthalmology. 2012;119(4):819–26.
Hamel CP. Cone rod dystrophies. Orphanet J Rare Dis. 2007;2:7.
Aleman T, Uyhazi K, Serrano L, Vasireddy V, Bowman S, Ammar M, et al. RDH12 mutations cause a severe retinal degeneration with relatively spared extramacular rod function. submitted.
Ferrucci S, Anderson SF, Townsend JC. Retinitis pigmentosa inversa. Optom Vis Sci. 1998;75(8):560–70.
Usher CH. On the inheritance of retinitis pigmentosa, with notes of cases. R Lond Ophthalmol Hosp Rep. 1914;19:130–236.
Usher CH. The Bowman lecture: on a few hereditary eye affections. Trans Ophthal Soc UK. 1935;55:164–245.
Gettelfinger JD, Dahl JP. Syndromic hearing loss: a brief review of common presentations and genetics. J Pediatr Genet. 2018;7(1):1–8.
Kimberling WJ, Hildebrand MS, Shearer AE, Jensen ML, Halder JA, Trzupek K, et al. Frequency of Usher syndrome in two pediatric populations: implications for genetic screening of deaf and hard of hearing children. Genet Med. 2010;12(8):512–6.
Cosgrove D, Zallocchi M. Usher protein functions in hair cells and photoreceptors. Int J Biochem Cell Biol. 2014;46:80–9.
Hunter DG, Fishman GA, Mehta RS, Kretzer FL. Abnormal sperm and photoreceptor axonemes in Usher’s syndrome. Arch Ophthalmol. 1986;104(3):385–9.
Berson EL, Adamian M. Ultrastructural findings in an autopsy eye from a patient with Usher’s syndrome type II. Am J Ophthalmol. 1992;114(6):748–57.
Gibbs D, Kitamoto J, Williams DS. Abnormal phagocytosis by retinal pigmented epithelium that lacks myosin VIIa, the Usher syndrome 1B protein. Proc Natl Acad Sci U S A. 2003;100(11):6481–6.
Williams DS. Usher syndrome: animal models, retinal function of Usher proteins, and prospects for gene therapy. Vis Res. 2008;48(3):433–41.
Williams DS, Aleman TS, Lillo C, Lopes VS, Hughes LC, Stone EM, et al. Harmonin in the murine retina and the retinal phenotypes of Ush1c-mutant mice and human USH1C. Invest Ophthalmol Vis Sci. 2009;50(8):3881–9.
Phillips JB, Blanco-Sanchez B, Lentz JJ, Tallafuss A, Khanobdee K, Sampath S, et al. Harmonin (Ush1c) is required in zebrafish Muller glial cells for photoreceptor synaptic development and function. Dis Model Mech. 2011;4(6):786–800.
Bujakowska KM, Consugar M, Place E, Harper S, Lena J, Taub DG, et al. Targeted exon sequencing in Usher syndrome type I. Invest Ophthalmol Vis Sci. 2014;55(12):8488–96.
Fishman G, Vasquez V, Fishman M, Berger D. Visual loss and foveal lesions in Usher’s syndrome. Br J Ophthalmol. 1979;63(7):484–8.
Fishman GA, Anderson RJ, Lam BL, Derlacki DJ. Prevalence of foveal lesions in type 1 and type 2 Usher’s syndrome. Arch Ophthalmol. 1995;113(6):770–3.
Fishman GA, Kumar A, Joseph ME, Torok N, Anderson RJ. Usher’s syndrome. Ophthalmic and neuro-otologic findings suggesting genetic heterogeneity. Arch Ophthalmol. 1983;101(9):1367–74.
Sankila EM, Pakarinen L, Kaariainen H, Aittomaki K, Karjalainen S, Sistonen P, et al. Assignment of an Usher syndrome type III (USH3) gene to chromosome 3q. Hum Mol Genet. 1995;4(1):93–8.
Gerber S, Bonneau D, Gilbert B, Munnich A, Dufier JL, Rozet JM, et al. USH1A: chronicle of a slow death. Am J Hum Genet. 2006;78(2):357–9.
Khateb S, Zelinger L, Mizrahi-Meissonnier L, Ayuso C, Koenekoop RK, Laxer U, et al. A homozygous nonsense CEP250 mutation combined with a heterozygous nonsense C2orf71 mutation is associated with atypical Usher syndrome. J Med Genet. 2014;51(7):460–9.
Namburi P, Ratnapriya R, Khateb S, Lazar Csilla H, Kinarty Y, Obolensky A, et al. Bi-allelic truncating mutations in CEP78, encoding centrosomal protein 78, cause cone-rod degeneration with sensorineural hearing loss. Am J Hum Genet. 2016;99(3):777–84.
Fu Q, Xu M, Chen X, Sheng X, Yuan Z, Liu Y, et al. CEP78 is mutated in a distinct type of Usher syndrome. J Med Genet. 2017;54(3):190–5.
Khateb S, Kowalewski B, Bedoni N, Damme M, Pollack N, Saada A, et al. A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans. Genet Med. 2018;20(9):1004–12.
Peter VG, Quinodoz M, Sadio S, Held S, Rodrigues M, Soares M, et al. New clinical and molecular evidence linking mutations in ARSG to Usher syndrome type IV. Hum Mutat. 2021;42(3):261–71.
Fillman RD, Leguire LE, Rogers GL, Bremer DL, Fellows RR. Screening for vision problems, including Usher’s syndrome, among hearing impaired students. Am Ann Deaf. 1987;132(3):194–8.
Young NM, Mets MB, Hain TC. Early diagnosis of Usher syndrome in infants and children. Am J Otol. 1996;17(1):30–4.
Mets MB, Young NM, Pass A, Lasky JB. Early diagnosis of Usher syndrome in children. Trans Am Ophthalmol Soc. 2000;98:237–42; discussion 43–5
West SK, Hindocha M, Hogg CR, Holder GE, Moore AT, Reddy MA. Electroretinogram assessment of children with sensorineural hearing loss: implications for screening. J AAPOS. 2015;19(5):450–4.
Pennings RJ, Topsakal V, Astuto L, de Brouwer AP, Wagenaar M, Huygen PL, et al. Variable clinical features in patients with CDH23 mutations (USH1D-DFNB12). Otol Neurotol. 2004;25(5):699–706.
Schultz JM, Bhatti R, Madeo AC, Turriff A, Muskett JA, Zalewski CK, et al. Allelic hierarchy of CDH23 mutations causing non-syndromic deafness DFNB12 or Usher syndrome USH1D in compound heterozygotes. J Med Genet. 2011;48(11):767–75.
Schwartz SB, Aleman TS, Cideciyan AV, Windsor EA, Sumaroka A, Roman AJ, et al. Disease expression in Usher syndrome caused by VLGR1 gene mutation (USH2C) and comparison with USH2A phenotype. Invest Ophthalmol Vis Sci. 2005;46(2):734–43.
Jacobson SG, Cideciyan AV, Aleman TS, Sumaroka A, Roman AJ, Gardner LM, et al. Usher syndromes due to MYO7A, PCDH15, USH2A or GPR98 mutations share retinal disease mechanism. Hum Mol Genet. 2008;17(15):2405–15.
Herrera W, Aleman TS, Cideciyan AV, Roman AJ, Banin E, Ben-Yosef T, et al. Retinal disease in Usher syndrome III caused by mutations in the clarin-1 gene. Invest Ophthalmol Vis Sci. 2008;49(6):2651–60.
Jacobson SG, Aleman TS, Sumaroka A, Cideciyan AV, Roman AJ, Windsor EAM, et al. Disease boundaries in the retina of patients with Usher syndrome caused by MYO7A gene mutations. Invest Ophthalmol Vis Sci. 2009;50(4):1886.
Jacobson SG, Cideciyan AV, Gibbs D, Sumaroka A, Roman AJ, Aleman TS, et al. Retinal disease course in Usher syndrome 1B due to MYO7A mutations. Invest Ophthalmol Vis Sci. 2011;52(11):7924–36.
Berson E, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111:761–72.
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004;122(9):1306–14.
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004;122(9):1297–305.
Williams DS, Chadha A, Hazim R, Gibbs D. Gene therapy approaches for prevention of retinal degeneration in Usher syndrome. Gene Ther. 2017;24(2):68–71.
Lopes VS, Boye SE, Louie CM, Boye S, Dyka F, Chiodo V, et al. Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther. 2013;20:824.
Laurence JZ, Moon RC. Four cases of ‘retinitis pigmentosa’, occurring in the same family, and accompanied by general imperfections of development. Ophthalmic Rev (Old Series). 1866;2:32–41.
Hutchinson J. Slowly progressive paraplegia and disease of the choroids with defective intellect and arrested sexual development in several brothers and a sister. Arch Surg (Lond). 1900;11:118–22.
Bardet G. Sur un syndrome d’obésité congénitale avec polydactylie et rétinite pigmentaire (contribution à l’étude des formes cliniques de l’obésité hypophysaire). Université de Paris, Thesis no 470, Legrand. 1920.
Biedl A. Ein Geschwisterpaar mit adiposo-genitaler Dystrophie. Dtsch Med Wochenschr. 1922;48:1630.
Mockel A, Perdomo Y, Stutzmann F, Letsch J, Marion V, Dollfus H. Retinal dystrophy in Bardet–Biedl syndrome and related syndromic ciliopathies. Prog Retin Eye Res. 2011;30(4):258–74.
Schachat AP, Maumenee IH. Bardet-Biedl syndrome and related disorders. Arch Ophthalmol. 1982;100(2):285–8.
Campo RV, Aaberg TM. Ocular and systemic manifestations of the Bardet-Biedl syndrome. Am J Ophthalmol. 1982;94(6):750–6.
Chen J, Smaoui N, Hammer MB, Jiao X, Riazuddin SA, Harper S, et al. Molecular analysis of Bardet-Biedl syndrome families: report of 21 novel mutations in 10 genes. Invest Ophthalmol Vis Sci. 2011;52(8):5317–24.
Daniels AB, Sandberg MA, Chen J, Weigel-DiFranco C, Fielding Hejtmancic J, Berson EL. Genotype-phenotype correlations in Bardet-Biedl syndrome. Arch Ophthalmol. 2012;130(7):901–7.
Rizzo JF 3rd, Berson EL, Lessell S. Retinal and neurologic findings in the Laurence-Moon-Bardet-Biedl phenotype. Ophthalmology. 1986;93(11):1452–6.
O’Neil E, Serrano L, Scoles D, Cunningham KE, Han G, Chiang J, et al. Detailed retinal phenotype of Boucher-Neuhauser syndrome associated with mutations in PNPLA6 mimicking choroideremia. Ophthalmic Genet. 2019;40(3):267–75.
Leys MJ, Schreiner LA, Hansen RM, Mayer DL, Fulton AB. Visual acuities and dark-adapted thresholds of children with Bardet-Biedl syndrome. Am J Ophthalmol. 1988;106(5):561–9.
Fulton AB, Hansen RM, Glynn RJ. Natural course of visual functions in the Bardet-Biedl syndrome. Arch Ophthalmol. 1993;111(11):1500–6.
Riise R, Andreasson S, Borgastrom MK, Wright AF, Tommerup N, Rosenberg T, et al. Intrafamilial variation of the phenotype in Bardet-Biedl syndrome. Br J Ophthalmol. 1997;81(5):378–85.
Scheidecker S, Hull S, Perdomo Y, Studer F, Pelletier V, Muller J, et al. Predominantly cone-system dysfunction as rare form of retinal degeneration in patients with molecularly confirmed Bardet-Biedl syndrome. Am J Ophthalmol. 2015;160(2):364–72. e1
Heon E, Kim G, Qin S, Garrison JE, Tavares E, Vincent A, et al. Mutations in C8ORF37 cause Bardet Biedl syndrome (BBS21). Hum Mol Genet. 2016;25(11):2283–94.
Suspitsin EN, Imyanitov EN. Bardet-Biedl syndrome. Mol Syndromol. 2016;7(2):62–71.
Kagan KO, Dufke A, Gembruch U. Renal cystic disease and associated ciliopathies. Curr Opin Obstet Gynecol. 2017;29(2):85–94.
Tsang SH, Aycinena ARP, Sharma T. Ciliopathy: Bardet-Biedl syndrome. Adv Exp Med Biol. 2018;1085:171–4.
Krill AE, Folk E, Rosenthal IM. Electroretinography in the Laurence-Moon-Biedl syndrome. An aid in diagnosis of the atypical case. Am J Dis Child. 1961;102:205–9.
Jacobson SG, Borruat FX, Apathy PP. Patterns of rod and cone dysfunction in Bardet-Biedl syndrome. Am J Ophthalmol. 1990;109(6):676–88.
Heon E, Westall C, Carmi R, Elbedour K, Panton C, Mackeen L, et al. Ocular phenotypes of three genetic variants of Bardet-Biedl syndrome. Am J Med Genet A. 2005;132A(3):283–7.
Abu-Safieh L, Al-Anazi S, Al-Abdi L, Hashem M, Alkuraya H, Alamr M, et al. In search of triallelism in Bardet-Biedl syndrome. Eur J Hum Genet. 2012;20(4):420–7.
Katsanis N, Ansley SJ, Badano JL, Eichers ER, Lewis RA, Hoskins BE, et al. Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science. 2001;293(5538):2256–9.
Beales PL, Badano JL, Ross AJ, Ansley SJ, Hoskins BE, Kirsten B, et al. Genetic interaction of BBS1 mutations with alleles at other BBS loci can result in non-Mendelian Bardet-Biedl syndrome. Am J Hum Genet. 2003;72(5):1187–99.
Badano JL, Leitch CC, Ansley SJ, May-Simera H, Lawson S, Lewis RA, et al. Dissection of epistasis in oligogenic Bardet-Biedl syndrome. Nature. 2006;439(7074):326–30.
Simons DL, Boye SL, Hauswirth WW, Wu SM. Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet-Biedl syndrome mouse model. Proc Natl Acad Sci U S A. 2011;108(15):6276–81.
Seo S, Mullins RF, Dumitrescu AV, Bhattarai S, Gratie D, Wang K, et al. Subretinal gene therapy of mice with Bardet-Biedl syndrome type 1. Invest Ophthalmol Vis Sci. 2013;54(9):6118–32.
Sharon D. Shared mutations in NR2E3 in enhanced S-cone syndrome, Goldmann-Favre syndrome, and many cases of clumped pigmentary retinal degeneration. Arch Ophthalmol. 2003;121(9):1316.
Schorderet DF, Escher P. NR2E3 mutations in enhanced S-cone sensitivity syndrome (ESCS), Goldmann-Favre syndrome (GFS), clumped pigmentary retinal degeneration (CPRD), and retinitis pigmentosa (RP). Hum Mutat. 2009;30(11):1475–85.
Jacobson SG, Marmor MF, Kemp CM, Knighton RW. SWS (blue) cone hypersensitivity in a newly identified retinal degeneration. Invest Ophthalmol Vis Sci. 1990;31(5):827–38.
Marmor MF, Jacobson SG, Foerster MH, Kellner U, Weleber RG. Diagnostic clinical findings of a new syndrome with night blindness, maculopathy, and enhanced S cone sensitivity. Am J Ophthalmol. 1990;110(2):124–34.
Jacobson SG, Roman AJ, Roman MI, Gass JD, Parker JA. Relatively enhanced S cone function in the Goldmann-Favre syndrome. Am J Ophthalmol. 1991;111(4):446–53.
Roman AJ, Jacobson SG. S cone-driven but not S cone-type electroretinograms in the enhanced S cone syndrome. Exp Eye Res. 1991;53(5):685–90.
Audo I, Michaelides M, Robson AG, Hawlina M, Vaclavik V, Sandbach JM, et al. Phenotypic variation in enhanced S-cone syndrome. Invest Ophthalmol Vis Sci. 2008;49(5):2082.
Milam AH, Rose L, Cideciyan AV, Barakat MR, Tang WX, Gupta N, et al. The nuclear receptor NR2E3 plays a role in human retinal photoreceptor differentiation and degeneration. Proc Natl Acad Sci U S A. 2002;99(1):473–8.
Greenstein VC, Zaidi Q, Hood DC, Spehar B, Cideciyan AV, Jacobson SG. The enhanced S cone syndrome: an analysis of receptoral and post-receptoral changes. Vis Res. 1996;36(22):3711–22.
Udar N, Small K, Chalukya M, Silva-Garcia R, Marmor M. Developmental or degenerative – NR2E3 gene mutations in two patients with enhanced S cone syndrome. Mol Vis. 2011;17:519–25.
Hull S, Arno G, Sergouniotis PI, Tiffin P, Borman AD, Chandra A, et al. Clinical and molecular characterization of enhanced S-cone syndrome in children. JAMA Ophthalmol. 2014;132(11):1341.
Ripamonti C, Aboshiha J, Henning GB, Sergouniotis PI, Michaelides M, Moore AT, et al. Vision in observers with enhanced S-cone syndrome: an excess of S-cones but connected mainly to conventional S-cone pathways. Invest Ophthalmol Vis Sci. 2014;55(2):963.
Collison FT, Park JC, Fishman GA, Stone EM, McAnany JJ. Two-color pupillometry in enhanced S-cone syndrome caused by NR2E3 mutations. Doc Ophthalmol. 2016;132(3):157–66.
Coppieters F, Leroy BP, Beysen D, Hellemans J, De Bosscher K, Haegeman G, et al. Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa. Am J Hum Genet. 2007;81(1):147–57.
Garafalo AV, Calzetti G, Cideciyan AV, Roman AJ, Saxena S, Sumaroka A, et al. Cone vision changes in the enhanced S-cone syndrome caused by NR2E3 gene mutations. Invest Ophthalmol Vis Sci. 2018;59(8):3209.
Ammar MJ, Scavelli KT, Uyhazi KE, Bedoukian EC, Serrano LW, Edelstein ID, et al. Enhanced S-cone syndrome: visual function, cross-sectional imaging, and cellular structure with adaptive optics ophthalmoscopy. Retin Cases Brief Rep. 2019. https://doi.org/10.1097/ICB.0000000000000891. Epub ahead of print.
Swaroop A, Xu JZ, Pawar H, Jackson A, Skolnick C, Agarwal N. A conserved retina-specific gene encodes a basic motif/leucine zipper domain. Proc Natl Acad Sci U S A. 1992;89(1):266–70.
Haider NB, Jacobson SG, Cideciyan AV, Swiderski R, Streb LM, Searby C, et al. Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet. 2000;24:127–31.
Cheng H, Aleman TS, Cideciyan AV, Khanna R, Jacobson SG, Swaroop A. In vivo function of the orphan nuclear receptor NR2E3 in establishing photoreceptor identity during mammalian retinal development. Hum Mol Genet. 2006;15(17):2588–602.
Kanda A, Swaroop A. A comprehensive analysis of sequence variants and putative disease-causing mutations in photoreceptor-specific nuclear receptor NR2E3. Mol Vis. 2009;15:2174–84.
Hoshino A, Ratnapriya R, Brooks MJ, Chaitankar V, Wilken MS, Zhang C, et al. Molecular anatomy of the developing human retina. Dev Cell. 2017;43(6):763–79.e4.
Nishiguchi KM, Friedman JS, Sandberg MA, Swaroop A, Berson EL, Dryja TP. Recessive NRL mutations in patients with clumped pigmentary retinal degeneration and relative preservation of blue cone function. Proc Natl Acad Sci U S A. 2004;101(51):17819–24.
Newman H, Blumen SC, Braverman I, Hanna R, Tiosano B, Perlman I, et al. Homozygosity for a recessive loss-of-function mutation of the NRL gene is associated with a variant of enhanced S-cone syndrome. Invest Ophthalmol Vis Sci. 2016;57(13):5361.
Vaclavik V, Chakarova C, Bhattacharya SS, Robson AG, Holder GE, Bird AC, et al. Bilateral giant macular schisis in a patient with enhanced S-cone syndrome from a family showing pseudo-dominant inheritance. Br J Ophthalmol. 2008;92(2):299–300.
Park SP, Hong IH, Tsang SH, Lee W, Horowitz J, Yzer S, et al. Disruption of the human cone photoreceptor mosaic from a defect in NR2E3 transcription factor function in young adults. Graefes Arch Clin Exp Ophthalmol. 2013;251(10):2299–309.
Pachydaki SI, Klaver CC, Barbazetto IA, Roy MS, Gouras P, Allikmets R, et al. Phenotypic features of patients with NR2E3 mutations. Arch Ophthalmol. 2009;127(1):71–5.
Sohn EH, Chen FK, Rubin GS, Moore AT, Webster AR, MacLaren RE. Macular function assessed by microperimetry in patients with enhanced S-cone syndrome. Ophthalmology. 2010;117(6):1199–206.e1.
Pachydaki SI, Bhatnagar PA, Barbazetto IA, Klaver CC, Freund BK, Yannuzzi LA. Long-term follow-up in enhanced s-cone syndrome. Retin Cases Brief Rep. 2009;3(2):118–20.
Bandah D, Merin S, Ashhab M, Banin E, Sharon D. The spectrum of retinal diseases caused by NR2E3 mutations in Israeli and Palestinian patients. Arch Ophthalmol. 2009;127(3):297–302.
Fishman GA, Jampol LM, Goldberg MF. Diagnostic features of the Favre-Goldmann syndrome. Br J Ophthalmol. 1976;60(5):345–53.
Yzer S, Barbazetto I, Allikmets R, van Schooneveld MJ, Bergen A, Tsang SH, et al. Expanded clinical spectrum of enhanced S-cone syndrome. JAMA Ophthalmol. 2013;131(10):1324–30.
Hood DC, Cideciyan AV, Roman AJ, Jacobson SG. Enhanced S cone syndrome: evidence for an abnormally large number of S cones. Vis Res. 1995;35(10):1473–81.
Fishman GA, Peachey NS. Rod-cone dystrophy associated with a rod system electroretinogram obtained under photopic conditions. Ophthalmology. 1989;96(6):913–8.
Jacobson SG, Sumaroka A, Aleman TS, Cideciyan AV, Schwartz SB, Roman AJ, et al. Nuclear receptor NR2E3 gene mutations distort human retinal laminar architecture and cause an unusual degeneration. Hum Mol Genet. 2004;13(17):1893–902.
Roman AJ, Powers CA, Semenov EP, Sheplock R, Aksianiuk V, Russell RC, et al. Short-wavelength sensitive cone (S-cone) testing as an outcome measure for NR2E3 clinical treatment trials. Int J Mol Sci. 2019;20(10):2497.
Kurstjens JH. Choroideremia and gyrate atrophy of the choroid and retina. Doc Ophthalmol. 1965;19(1):1–122.
McCulloch C. Choroideremia: a clinical and pathologic review. Trans Am Ophthalmol Soc. 1969;67:142–95.
MacDonald IM, Russell L, Chan C-C. Choroideremia: new findings from ocular pathology and review of recent literature. Surv Ophthalmol. 2009;54(3):401–7.
Karna J. Choroideremia. A clinical and genetic study of 84 Finnish patients and 126 female carriers. Copenhagen. Arch Ophthalmol Suppl. 1986;176:1–68.
McCulloch C, McCulloch R. A hereditary and clinical study of choroideremia. Trans Am Acad Ophthalmol Otolaryngol. 1948;52:160–90.
Hayakawa M, Fujiki K, Hotta Y, Ito R, Ohki J, Ono J, et al. Visual impairment and REP-1 gene mutations in Japanese choroideremia patients. Ophthalmic Genet. 1999;20(2):107–15.
Duncan JL, Aleman TS, Gardner LM, De Castro E, Marks DA, Emmons JM, et al. Macular pigment and lutein supplementation in choroideremia. Exp Eye Res. 2002;74(3):371–81.
Jacobson SG, Cideciyan AV, Sumaroka A, Aleman TS, Schwartz SB, Windsor EA, et al. Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations. Invest Ophthalmol Vis Sci. 2006;47(9):4113–20.
Aleman T, Morgan J, Serrano L, Han H, Fuerst N, Charlson E, et al. Natural history of the central structural abnormalities in choroideremia: a prospective cross-sectional study. Ophthalmology. 2017;124:359–73.
Roberts MF, Fishman GA, Roberts DK, Heckenlively JR, Weleber RG, Anderson RJ, et al. Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia. Br J Ophthalmol. 2002;86(6):658–62.
Heon E, Alabduljalil T, McGuigan ID, Cideciyan AV, Li S, Chen S, et al. Visual function and central retinal structure in choroideremia. Invest Ophthalmol Vis Sci. 2016;57(9):OCT377–87.
Nabholz N, Lorenzini M-C, Bocquet B, Lacroux A, Faugère V, Roux A-F, et al. Clinical evaluation and cone alterations in choroideremia. Ophthalmology. 2016;123(8):1830–2.
Coussa RG, Traboulsi EI. Choroideremia: a review of general findings and pathogenesis. Ophthalmic Genet. 2012;33(2):57–65.
Seitz IP, Zhour A, Kohl S, Llavona P, Peter T, Wilhelm B, et al. Multimodal assessment of choroideremia patients defines pre-treatment characteristics. Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2143–50.
Pameyer JK, Waardenburg PJ, Henkes HE. Choroid eremia. Br J Ophthalmol. 1960;44:724–38.
O’Neil E, Uyhazi, KE, Connor, KO, Aleman, IA, Pulido, JS, Rossano, JW, Aleman, TS. Danon disease: a model of photoreceptor degeneration secondary to primary retinal pigment epithelium disease. Retina Cases Brief Rep. 2021.
Bozbeyoglu S, Fishman GA, Stone EM, MacDonald IM, Streb LM. De novo mutation in a choroideremia carrier. Retin Cases Brief Rep. 2007;1(3):182–4.
Jauregui R, Park KS, Tanaka AJ, Cho A, Paavo M, Zernant J, et al. Spectrum of disease severity and phenotype in choroideremia carriers. Am J Ophthalmol. 2019;207:77–86.
Simell O, Takki K. Raised plasma-ornithine and gyrate atrophy of the choroid and retina. Lancet. 1973;1(7811):1031–3.
Valle D, Kaiser-Kupfer MI, Del Valle LA. Gyrate atrophy of the choroid and retina: deficiency of ornithine aminotransferase in transformed lymphocytes. Proc Natl Acad Sci U S A. 1977;74(11):5159–61.
Trijbels JM, Sengers RC, Bakkeren JA, De Kort AF, Deutman AF. L-ornithine-ketoacid-transaminase deficiency in cultured fibroblasts of a patient with hyperornithinaemia and gyrate atrophy of the choroid and retina. Clin Chim Acta. 1977;79(2):371–7.
Berson EL, Schmidt SY, Rabin AR. Plasma amino-acids in hereditary retinal disease. Ornithine, lysine, and taurine. Br J Ophthalmol. 1976;60(2):142–7.
Takki K, Simell O. Genetic aspects in gyrate atrophy of the choroid and retina with hyperornithinaemia. Br J Ophthalmol. 1974;58(11):907–16.
Potter MJ, Berson EL. Diagnosis and treatment of gyrate atrophy. Int Ophthalmol Clin. 1993;33(2):229–36.
Kaiser-Kupfer MIV, D.L. Clinical, biochemical, and therapeutic aspects of gyrate atrophy. Prog Retin Res. 1987;6:179.
Li A, Jiao X, Munier FL, Schorderet DF, Yao W, Iwata F, et al. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am J Hum Genet. 2004;74(5):817–26.
Mataftsi A, Zografos L, Milla E, Secretan M, Munier FL. Bietti’s crystalline corneoretinal dystrophy: a cross-sectional study. Retina. 2004;24(3):416–26.
Nakano M, Kelly EJ, Wiek C, Hanenberg H, Rettie AE. CYP4V2 in Bietti’s crystalline dystrophy: ocular localization, metabolism of omega-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant. Mol Pharmacol. 2012;82(4):679–86.
Garcia-Garcia GP, Martinez-Rubio M, Moya-Moya MA, Perez-Santonja JJ, Escribano J. Current perspectives in Bietti crystalline dystrophy. Clin Ophthalmol. 2019;13:1379–99.
Fuerst NM, Serrano L, Han G, Morgan JI, Maguire AM, Leroy BP, et al. Detailed functional and structural phenotype of Bietti crystalline dystrophy associated with mutations in CYP4V2 complicated by choroidal neovascularization. Ophthalmic Genet. 2016;37(4):445–52.
Lee J, Jiao X, Hejtmancik JF, Kaiser-Kupfer M, Chader GJ. Identification, isolation, and characterization of a 32-kDa fatty acid-binding protein missing from lymphocytes in humans with Bietti crystalline dystrophy (BCD). Mol Genet Metab. 1998;65(2):143–54.
Kaiser-Kupfer MI, Chan CC, Markello TC, Crawford MA, Caruso RC, Csaky KG, et al. Clinical biochemical and pathologic correlations in Bietti’s crystalline dystrophy. Am J Ophthalmol. 1994;118(5):569–82.
Zhang X, Xu K, Dong B, Peng X, Li Q, Jiang F, et al. Comprehensive screening of CYP4V2 in a cohort of Chinese patients with Bietti crystalline dystrophy. Mol Vis. 2018;24:700–11.
Atmaca LS, Muftuoglu O, Atmaca-Sonmez P. Peripapillary choroidal neovascularization in Bietti crystalline retinopathy. Eye (Lond). 2007;21(6):839–42.
Lockhart CM, Smith TB, Yang P, Naidu M, Rettie AE, Nath A, et al. Longitudinal characterisation of function and structure of Bietti crystalline dystrophy: report on a novel homozygous mutation in CYP4V2. Br J Ophthalmol. 2018;102(2):187–94.
Oishi A, Oishi M, Miyata M, Hirashima T, Hasegawa T, Numa S, et al. Multimodal imaging for differential diagnosis of Bietti crystalline dystrophy. Ophthalmol Retina. 2018;2(10):1071–7.
Miyata M, Hata M, Ooto S, Ogino K, Gotoh N, Morooka S, et al. Choroidal and retinal atrophy of Bietti crystalline dystrophy patients with Cyp4v2 mutations compared to retinitis pigmentosa patients with Eys mutations. Retina. 2017;37(6):1193–202.
Gupta B, Parvizi S, Mohamed MD. Bietti crystalline dystrophy and choroidal neovascularisation. Int Ophthalmol. 2011;31(1):59–61.
Li Q, Li Y, Zhang X, Xu Z, Zhu X, Ma K, et al. Utilization of fundus autofluorescence, spectral domain optical coherence tomography, and enhanced depth imaging in the characterization of Bietti crystalline dystrophy in different stages. Retina. 2015;35(10):2074–84.
Mamatha G, Umashankar V, Kasinathan N, Krishnan T, Sathyabaarathi R, Karthiyayini T, et al. Molecular screening of the CYP4V2 gene in Bietti crystalline dystrophy that is associated with choroidal neovascularization. Mol Vis. 2011;17:1970–7.
Kobat SG, Gul FC, Yusufoglu E. Bietti crystalline dystrophy and choroidal neovascularization in childhood. Int J Ophthalmol. 2019;12(9):1514–6.
Aleman TS, Han G, Serrano LW, Fuerst NM, Charlson ES, Pearson DJ, et al. Natural history of the central structural abnormalities in choroideremia: a prospective cross-sectional study. Ophthalmology. 2017;124(3):359–73.
Lockhart CM, Nakano M, Rettie AE, Kelly EJ. Generation and characterization of a murine model of Bietti crystalline dystrophy. Invest Ophthalmol Vis Sci. 2014;55(9):5572–81.
Song WK, Clouston P, MacLaren RE. Presence of corneal crystals confirms an unusual presentation of Bietti’s retinal dystrophy. Ophthalmic Genet. 2019;40:1–5.
Kovach JL, Isildak H, Sarraf D. Crystalline retinopathy: unifying pathogenic pathways of disease. Surv Ophthalmol. 2019;64(1):1–29.
Hata M, Ikeda HO, Iwai S, Iida Y, Gotoh N, Asaka I, et al. Reduction of lipid accumulation rescues Bietti’s crystalline dystrophy phenotypes. Proc Natl Acad Sci U S A. 2018;115(15):3936–41.
Zeitz C, Robson AG, Audo I. Congenital stationary night blindness: an analysis and update of genotype-phenotype correlations and pathogenic mechanisms. Prog Retin Eye Res. 2015;45:58–110.
Schubert G, Bornschein H. Analysis of the human electroretinogram. Ophthalmologica. 1952;123(6):396–413.
Snyder C. Jean Nougaret, the butcher from Provence, and his family. Arch Ophthalmol. 1963;69:676–8.
Carr RE. Congenital stationary nightblindness. Trans Am Ophthalmol Soc. 1974;72:448–87.
Sandberg MA, Pawlyk BS, Dan J, Arnaud B, Dryja TP, Berson EL. Rod and cone function in the Nougaret form of stationary night blindness. Arch Ophthalmol. 1998;116(7):867–72.
Kabanarou SA, Holder GE, Fitzke FW, Bird AC, Webster AR. Congenital stationary night blindness and a “Schubert-Bornschein” type electrophysiology in a family with dominant inheritance. Br J Ophthalmol. 2004;88(8):1018–22.
Riggs LA. Electroretinography in cases of night blindness. Am J Ophthalmol. 1954;38(1–2):70–8.
Miyake Y, Yagasaki K, Horiguchi M, Kawase Y, Kanda T. Congenital stationary night blindness with negative electroretinogram. A new classification. Arch Ophthalmol. 1986;104(7):1013–20.
Dryja TP. Molecular genetics of Oguchi disease, fundus albipunctatus, and other forms of stationary night blindness: LVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2000;130(5):547–63.
Krill AE, Martin D. Photopic abnormalities in congenital stationary nightblindness. Investig Ophthalmol. 1971;10(8):625–36.
Heckenlively JR, Martin DA, Rosenbaum AL. Loss of electroretinographic oscillatory potentials, optic atrophy, and dysplasia in congenital stationary night blindness. Am J Ophthalmol. 1983;96(4):526–34.
Lachapelle P, Little JM, Polomeno RC. The photopic electroretinogram in congenital stationary night blindness with myopia. Invest Ophthalmol Vis Sci. 1983;24(4):442–50.
Alexander KR, Fishman GA, Peachey NS, Marchese AL, Tso MO. ‘On’ response defect in paraneoplastic night blindness with cutaneous malignant melanoma. Invest Ophthalmol Vis Sci. 1992;33(3):477–83.
Tremblay F, Parkinson J. Gradient of deficit in cone responses in the incomplete form of congenital stationary night blindness revealed by multifocal electroretinography. Doc Ophthalmol. 2008;116(1):41–7.
Nishiguchi KM, Ikeda Y, Fujita K, Kunikata H, Akiho M, Hashimoto K, et al. Phenotypic features of Oguchi disease and retinitis pigmentosa in patients with S-antigen mutations: a long-term follow-up study. Ophthalmology. 2019;126(11):1557–66.
Cideciyan AV, Jacobson SG, Gupta N, Osawa S, Locke KG, Weiss ER, et al. Cone deactivation kinetics and GRK1/GRK7 expression in enhanced S cone syndrome caused by mutations in NR2E3. Invest Ophthalmol Vis Sci. 2003;44(3):1268–74.
Cideciyan AV, Zhao X, Nielsen L, Khani SC, Jacobson SG, Palczewski K. Null mutation in the rhodopsin kinase gene slows recovery kinetics of rod and cone phototransduction in man. Proc Natl Acad Sci U S A. 1998;95(1):328–33.
Fuchs S, Nakazawa M, Maw M, Tamai M, Oguchi Y, Gal A. A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat Genet. 1995;10(3):360–2.
Yamamoto S, Sippel K, Berson E, Dryja T. Defects in the rhodopsin kinase gene in the Oguchi form of stationary night blindness. Nat Genet. 1997;15(2):175–8.
Azam M, Collin RW, Khan MI, Shah ST, Qureshi N, Ajmal M, et al. A novel mutation in GRK1 causes Oguchi disease in a consanguineous Pakistani family. Mol Vis. 2009;15:1788–93.
Sonoyama H, Shinoda K, Ishigami C, Tada Y, Ideta H, Ideta R, et al. Oguchi disease masked by retinitis pigmentosa. Doc Ophthalmol. 2011;123(2):127–33.
Mooren A. Fünf Lustren ophthalmologischer Wirksamkeit. Wiesbaden: Bergmann; 1882.
Kurozumi I, Ohara M, Yasui T, Matuno C. Case of retinitis punctata albescens in a boy and degeneratio pigmentosa retinae sine pigmento in his sister. Rinsho Ganka. 1963;17:177–80.
Hipp S, Zobor G, Glockle N, Mohr J, Kohl S, Zrenner E, et al. Phenotype variations of retinal dystrophies caused by mutations in the RLBP1 gene. Acta Ophthalmol. 2015;93(4):e281–6.
Burstedt MS, Golovleva I. Central retinal findings in Bothnia dystrophy caused by RLBP1 sequence variation. Arch Ophthalmol. 2010;128(8):989–95.
Maw MA, Kennedy B, Knight A, Bridges R, Roth KE, Mani E, et al. Mutation of the gene encoding cellular retinaldehyde-binding protein in autosomal recessive retinitis pigmentosa. Nat Genet. 1997;17:198–200.
Burstedt MS, Sandgren O, Holmgren G, Forsman-Semb K. Bothnia dystrophy caused by mutations in the cellular retinaldehyde-binding protein gene (RLBP1) on chromosome 15q26. Invest Ophthalmol Vis Sci. 1999;40(5):995–1000.
Morimura H, Berson E, Dryja T. Recessive mutations in the RLBP1 gene encoding cellular retinaldehyde-binding protein in a form of retinitis punctata albescens. Invest Ophthalmol Vis Sci. 1999;40:1000–4.
Littink KW, van Genderen MM, van Schooneveld MJ, Visser L, Riemslag FC, Keunen JE, et al. A homozygous frameshift mutation in LRAT causes retinitis punctata albescens. Ophthalmology. 2012;119(9):1899–906.
Lauber H. Die sogenannte Retinitis punctata albescens. Klin Monatsbl Augenheilkd. 1910;48:133–48.
Carr RE, Margolis S, Siegel IM. Fluorescein angiography and vitamin A and oxalate levels in fundus albipunctatus. Am J Ophthalmol. 1976;82(4):549–58.
Sergouniotis PI, Sohn EH, Li Z, McBain VA, Wright GA, Moore AT, et al. Phenotypic variability in RDH5 retinopathy (Fundus Albipunctatus). Ophthalmology. 2011;118(8):1661–70.
Franceschetti A, Chome-Bercioux N. Fundus albipunctatus with hemeralopia of 49 years’ duration. Ophthalmologica. 1951;121(4):185–93.
Huber O, Franceschetti A, Dieterle P. Differential diagnosis of fundus albipunctatus with congenital hemeralopia from Oguchi’s disease. Ophthalmologica. 1957;133(4–5):283–7.
Bonnet JL, Ravault MP. Stationary retinitis punctata albescens (fundus albipunctatus cum hemeralopia). Bull Soc Ophtalmol Fr. 1965;65(5):467–9.
Cideciyan AV, Haeseleer F, Fariss RN, Aleman TS, Jang GF, Verlinde C, et al. Rod and cone visual cycle consequences of a null mutation in the 11-cis-retinol dehydrogenase gene in man. Vis Neurosci. 2000;17(5):667–78.
Marmor MF. Long-term follow-up of the physiologic abnormalities and fundus changes in fundus albipunctatus. Ophthalmology. 1990;97(3):380–4.
Niwa Y, Kondo M, Ueno S, Nakamura M, Terasaki H, Miyake Y. Cone and rod dysfunction in fundus albipunctatus with RDH5 mutation: an electrophysiological study. Invest Ophthalmol Vis Sci. 2005;46(4):1480–5.
Yamamoto H, Simon A, Eriksson U, Harris E, Berson E, Dryja T. Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. Nat Genet. 1999;22:188–91.
Naz S, Ali S, Riazuddin SA, Farooq T, Butt NH, Zafar AU, et al. Mutations in RLBP1 associated with fundus albipunctatus in consanguineous Pakistani families. Br J Ophthalmol. 2011;95(7):1019–24.
Schatz P, Preising M, Lorenz B, Sander B, Larsen M, Rosenberg T. Fundus albipunctatus associated with compound heterozygous mutations in RPE65. Ophthalmology. 2011;118(5):888–94.
Khan KN, Mahroo OA, Khan RS, Mohamed MD, McKibbin M, Bird A, et al. Differentiating drusen: drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. Prog Retin Eye Res. 2016;53:70–106.
Grant CA, Berson EL. Treatable forms of retinitis pigmentosa associated with systemic neurological disorders. Int Ophthalmol Clin. 2001;41(1):103–10.
Kearns TP. External ophthalmoplegia, pigmentary degeneration of the retina, and cardiomyopathy: a newly recognized syndrome. Trans Am Ophthalmol Soc. 1965;63:559–625.
Herzberg NH, van Schooneveld MJ, Bleeker-Wagemakers EM, Zwart R, Cremers FP, van der Knaap MS, et al. Kearns-Sayre syndrome with a phenocopy of choroideremia instead of pigmentary retinopathy. Neurology. 1993;43(1):218–21.
Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy. Proc Natl Acad Sci U S A. 1989;86(20):7952–6.
Daruich A, Matet A, Borruat FX. Macular dystrophy associated with the mitochondrial DNA A3243G mutation: pericentral pigment deposits or atrophy? Report of two cases and review of the literature. BMC Ophthalmol. 2014;14:77.
Rummelt V, Folberg R, Ionasescu V, Yi H, Moore KC. Ocular pathology of MELAS syndrome with mitochondrial DNA nucleotide 3243 point mutation. Ophthalmology. 1993;100(12):1757–66.
Schulz A, Kohlschutter A, Mink J, Simonati A, Williams R. NCL diseases – clinical perspectives. Biochim Biophys Acta. 2013;1832(11):1801–6.
Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161–78.
Aleman TS, Cideciyan AV, Volpe NJ, Stevanin G, Brice A, Jacobson SG. Spinocerebellar ataxia type 7 (SCA7) shows a cone-rod dystrophy phenotype. Exp Eye Res. 2002;74(6):737–45.
Martin JJ. Spinocerebellar ataxia type 7. Handb Clin Neurol. 2012;103:475–91.
Traboulsi EI, Maumenee IH, Green WR, Freimer ML, Moser H. Olivopontocerebellar atrophy with retinal degeneration. A clinical and ocular histopathologic study. Arch Ophthalmol. 1988;106(6):801–6.
Pula JH, Gomez CM, Kattah JC. Ophthalmologic features of the common spinocerebellar ataxias. Curr Opin Ophthalmol. 2010;21(6):447–53.
To KW, Adamian M, Jakobiec FA, Berson EL. Olivopontocerebellar atrophy with retinal degeneration. An electroretinographic and histopathologic investigation. Ophthalmology. 1993;100(1):15–23.
Niu C, Prakash TP, Kim A, Quach JL, Huryn LA, Yang Y, et al. Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7. Sci Transl Med. 2018;10(465):eaap8677.
Azevedo PB, Rocha AG, Keim LMN, Lavinsky D, Furtado GV, de Mattos EP, et al. Ophthalmological and neurologic manifestations in pre-clinical and clinical phases of spinocerebellar Ataxia type 7. Cerebellum. 2019;18(3):388–96.
Ramachandran PS, Bhattarai S, Singh P, Boudreau RL, Thompson S, Laspada AR, et al. RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration. PLoS One. 2014;9(4):e95362.
Collin GB, Marshall JD, Ikeda A, So WV, Russell-Eggitt I, Maffei P, et al. Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alstrom syndrome. Nat Genet. 2002;31(1):74–8.
Hearn T, Renforth GL, Spalluto C, Hanley NA, Piper K, Brickwood S, et al. Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alstrom syndrome. Nat Genet. 2002;31(1):79–83.
Alstrom CH, Hallgren B, Nilsson LB, Asander H. Retinal degeneration combined with obesity, diabetes mellitus and neurogenous deafness: a specific syndrome (not hitherto described) distinct from the Laurence-Moon-Bardet-Biedl syndrome: a clinical, endocrinological and genetic examination based on a large pedigree. Acta Psychiatr Neurol Scand Suppl. 1959;129:1–35.
Millay RH, Weleber RG, Heckenlively JR. Ophthalmologic and systemic manifestations of Alstrom’s disease. Am J Ophthalmol. 1986;102(4):482–90.
Aldrees A, Abdelkader E, Al-Habboubi H, Alrwebah H, Rahbeeni Z, Schatz P. Non-syndromic retinal dystrophy associated with homozygous mutations in the ALMS1 gene. Ophthalmic Genet. 2019;40(1):77–9.
Cockayne EA. Dwarfism with retinal atrophy and deafness. Arch Dis Child. 1936;11(61):1–8.
Pearce WG. Ocular and genetic features of Cockayne’s syndrome. Can J Ophthalmol. 1972;7(4):435–44.
Calmels N, Botta E, Jia N, Fawcett H, Nardo T, Nakazawa Y, et al. Functional and clinical relevance of novel mutations in a large cohort of patients with Cockayne syndrome. J Med Genet. 2018;55(5):329–43.
Weleber RG, Tongue AC, Kennaway NG, Budden SS, Buist NR. Ophthalmic manifestations of infantile phytanic acid storage disease. Arch Ophthalmol. 1984;102(9):1317–21.
Berson EL. Nutrition and retinal degenerations. Int Ophthalmol Clin. 2000;40(4):93–111.
Refsum S. Heredopathia atactica polyneuritiformis phytanic-acid storage disease, Refsum’s disease: a biochemically well-defined disease with a specific dietary treatment. Arch Neurol. 1981;38(10):605–6.
Klenk E, Kahlke W. Über das Vorkommen der 3,7,11,15-tetramethylhexadecansäure (Phytansäure) in den Cholesterinestern und anderen Lipoidfraktionen der Organe bei einem Krankheitsfall unbekannter Genese: Verdacht auf Heredopathia atactica polyneuritiformis (Refsum syndrome). Hoppe Seylers Z Physiol Chem. 1963;333:133–9.
Eldjarn L, Stokke O, Try K. Alpha-oxidation of branched chain fatty acids in man and its failure in patients with Refsum’s disease showing phytanic acid accumulation. Scand J Clin Lab Invest. 1966;18(6):694–5.
Ruether K, Baldwin E, Casteels M, Feher MD, Horn M, Kuranoff S, et al. Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy. Surv Ophthalmol. 2010;55(6):531–8.
Bassen FA, Kornzweig AL. Malformation of the erythrocytes in a case of atypical retinitis pigmentosa. Blood. 1950;5(4):381–7.
Singer K, Fisher B, Perlstein MA. Acanthrocytosis; a genetic erythrocytic malformation. Blood. 1952;7(6):577–91.
Jampel RS, Falls HF. Atypical retinitis pigmentosa, acanthrocytosis, and heredodegenerative neuromuscular disease. AMA Arch Ophthalmol. 1958;59(6):818–20.
Gouras P, Carr RE, Gunkel RD. Retinitis pigmentosa in abetalipoproteinemia: effects of vitamin A. Investig Ophthalmol. 1971;10(10):784–93.
Carr RE. Abetalipoproteinemia and the eye. Birth Defects Orig Artic Ser. 1976;12(3):385–408.
Cogan DG, Rodrigues M, Chu FC, Schaefer EJ. Ocular abnormalities in abetalipoproteinemia. A clinicopathologic correlation. Ophthalmology. 1984;91(8):991–8.
Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J Inherit Metab Dis. 2014;37(3):333–9.
Narcisi TM, Shoulders CC, Chester SA, Read J, Brett DJ, Harrison GB, et al. Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia. Am J Hum Genet. 1995;57(6):1298–310.
Aers XP, Leroy BP, Defesche JC, Shadid S. Abetalipoproteinemia from previously unreported gene mutations. Ann Intern Med. 2019;170(3):211–3.
Aleman TS, Garrity ST, Brucker AJ. Retinal structure in vitamin A deficiency as explored with multimodal imaging. Doc Ophthalmol. 2013;127(3):239–43.
Wong AM, Heon E. Helicoid peripapillary chorioretinal degeneration in abetalipoproteinemia. Arch Ophthalmol. 1998;116(2):250–1.
Alshareef RA, Bansal AS, Chiang A, Kaiser RS. Macular atrophy in a case of abetalipoproteinemia as only ocular clinical feature. Can J Ophthalmol. 2015;50(3):e43–6.
Fossdal R, Jonasson F, Kristjansdottir GT, Kong A, Stefansson H, Gosh S, et al. A novel TEAD1 mutation is the causative allele in Sveinsson’s chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration). Hum Mol Genet. 2004;13(9):975–81.
Bishara S, Merin S, Cooper M, Azizi E, Delpre G, Deckelbaum RJ. Combined vitamin A and E therapy prevents retinal electrophysiological deterioration in abetalipoproteinaemia. Br J Ophthalmol. 1982;66(12):767–70.
Cavalier L, Ouahchi K, Kayden HJ, Di Donato S, Reutenauer L, Mandel JL, et al. Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. Am J Hum Genet. 1998;62(2):301–10.
Aparicio JM, Belanger-Quintana A, Suarez L, Mayo D, Benitez J, Diaz M, et al. Ataxia with isolated vitamin E deficiency: case report and review of the literature. J Pediatr Gastroenterol Nutr. 2001;33(2):206–10.
Iwasa K, Shima K, Komai K, Nishida Y, Yokota T, Yamada M. Retinitis pigmentosa and macular degeneration in a patient with ataxia with isolated vitamin E deficiency with a novel c.717 del C mutation in the TTPA gene. J Neurol Sci. 2014;345(1–2):228–30.
Pang J, Kiyosawa M, Seko Y, Yokota T, Harino S, Suzuki J. Clinicopathological report of retinitis pigmentosa with vitamin E deficiency caused by mutation of the alpha-tocopherol transfer protein gene. Jpn J Ophthalmol. 2001;45(6):672–6.
Yokota T, Uchihara T, Kumagai J, Shiojiri T, Pang JJ, Arita M, et al. Postmortem study of ataxia with retinitis pigmentosa by mutation of the alpha-tocopherol transfer protein gene. J Neurol Neurosurg Psychiatry. 2000;68(4):521–5.
Thirkill CE, FitzGerald P, Sergott RC, Roth AM, Tyler NK, Keltner JL. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med. 1989;321(23):1589–94.
Thirkill CE. Cancer-induced retinal hypersensitivity. Br J Biomed Sci. 1996;53(3):227–34.
Mizener JB, Kimura AE, Adamus G, Thirkill CE, Goeken JA, Kardon RH. Autoimmune retinopathy in the absence of cancer. Am J Ophthalmol. 1997;123(5):607–18.
Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008;30(2):127–34.
Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev. 2009;8(5):410–4.
Grewal DS, Fishman GA, Jampol LM. Autoimmune retinopathy and antiretinal antibodies: a review. Retina. 2014;34(5):827–45.
Heckenlively JR, Lundy SK. Autoimmune retinopathy: an immunologic cellular-driven disorder. In: Ash JD, Anderson RE, LaVail MM, Bowes Rickman C, Hollyfield JG, Grimm C, editors. Retinal degenerative diseases, vol. 1074. Cham: Springer International Publishing; 2018. p. 193–201.
Aleman TS, Sandhu HS, Serrano LW, Traband A, Lau MK, Adamus G, et al. Acute zonal cone photoreceptor outer segment loss. JAMA Ophthalmol. 2017;135(5):487–90.
Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129(1):30–9.
Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–94.
Nair AA, Marmor MF. ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa. Doc Ophthalmol. 2017;134(3):175–83.
Roman AJ, Cideciyan AV, Schwartz SB, Olivares MB, Heon E, Jacobson SG. Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci. 2013;54(2):1378–83.
Yagasaki K, Jacobson SG, Apáthy PP, Knighton RW. Rod and cone psychophysics and electroretinography: methods for comparison in retinal degenerations. Doc Ophthalmol. 1988;69(2):119–30.
McGuigan DB 3rd, Roman AJ, Cideciyan AV, Matsui R, Gruzensky ML, Sheplock R, et al. Automated light- and dark-adapted perimetry for evaluating retinitis pigmentosa: filling a need to accommodate multicenter clinical trials. Invest Ophthalmol Vis Sci. 2016;57(7):3118–28.
Alexander KR, Fishman GA. Prolonged rod dark adaptation in retinitis pigmentosa. Br J Ophthalmol. 1984;68(8):561–9.
Bennett LD, Metz G, Klein M, Locke KG, Khwaja A, Birch DG. Regional variations and intra-/intersession repeatability for scotopic sensitivity in normal controls and patients with inherited retinal degenerations. Invest Ophthalmol Vis Sci. 2019;60(4):1122–31.
Peters AY, Locke KG, Birch DG. Comparison of the Goldmann-Weekers dark adaptometer and LKC technologies scotopic sensitivity tester-1. Doc Ophthalmol. 2000;101(1):1–9.
Cideciyan AV, Jacobson SG, Aleman TS, Gu D, Pearce-Kelling SE, Sumaroka A, et al. In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa. Proc Natl Acad Sci U S A. 2005;102(14):5233–8.
Tomasso L, Benatti L, Carnevali A, Mazzaferro A, Baldin G, Querques L, et al. Photobleaching by Spectralis fixation target. JAMA Ophthalmol. 2016;134(9):1060–2.
McCulloch DL, Marmor MF, Brigell MG, Hamilton R, Holder GE, Tzekov R, et al. ISCEV standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol. 2015;130(1):1–12.
Jacobson SG, Cideciyan AV, Kemp CM, Sheffield VC, Stone EM. Photoreceptor function in heterozygotes with insertion or deletion mutations in the RDS gene. Invest Ophthalmol Vis Sci. 1996;37(8):1662–74.
Birch DG, Fish GE. Rod ERGs in retinitis pigmentosa and cone-rod degeneration. Invest Ophthalmol Vis Sci. 1987;28(1):140–50.
Bonafede L, Ficicioglu CH, Serrano L, Han G, Morgan JI, Mills MD, et al. Cobalamin C deficiency shows a rapidly progressing maculopathy with severe photoreceptor and ganglion cell loss. Invest Ophthalmol Vis Sci. 2015;56(13):7875–87.
Wang S-j, C-z Y, Y-m L, Zhao Y-Y. Late-onset cobalamin C deficiency Chinese sibling patients with neuropsychiatric presentations: Metabolic Brain Disease; 2018.
Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol. 1988;106(9):1190–5.
Fishman GA, Gilbert LD, Anderson RJ, Marmor MF, Weleber RG, Viana MA. Effect of methazolamide on chronic macular edema in patients with retinitis pigmentosa. Ophthalmology. 1994;101(4):687–93.
Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006;141(5):850–8.
Park S, Lim LT, Gavin MP. Topical steroidal and nonsteroidal antiinflammatory drugs for the treatment of cystoid macular edema in retinitis pigmentosa. Retin Cases Brief Rep. 2013;7(2):134–6.
Strong SA, Peto T, Bunce C, Xing W, Georgiou M, Esposti SD, et al. Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa. Br J Ophthalmol. 2020;104(9):1203.
Naash ML, Peachey NS, Li ZY, Gryczan CC, Goto Y, Blanks J, et al. Light-induced acceleration of photoreceptor degeneration in transgenic mice expressing mutant rhodopsin. Invest Ophthalmol Vis Sci. 1996;37(5):775–82.
Paskowitz DM, LaVail MM, Duncan JL. Light and inherited retinal degeneration. Br J Ophthalmol. 2006;90(8):1060–6.
Ueda K, Kim HJ, Zhao J, Sparrow JR. Bisretinoid photodegradation is likely not a good thing. Adv Exp Med Biol. 2018;1074:395–401.
Grimm C, Reme CE. Light damage models of retinal degeneration. Methods Mol Biol. 2019;1834:167–78.
Berson EL. Light deprivation and retinitis pigmentosa. Vis Res. 1980;20(12):1179–84.
Cideciyan AV, Swider M, Aleman TS, Sumaroka A, Schwartz SB, Roman MI, et al. ABCA4-associated retinal degenerations spare structure and function of the human parapapillary retina. Invest Ophthalmol Vis Sci. 2005;46(12):4739–46.
Duncker T, Tabacaru MR, Lee W, Tsang SH, Sparrow JR, Greenstein VC. Comparison of near-infrared and short-wavelength autofluorescence in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2013;54(1):585–91.
Clark AJ, Yang P, Khaderi KR, Moshfeghi AA. Ocular tolerance of contemporary electronic display devices. Ophthalmic Surg Lasers Imaging Retina. 2018;49(5):346–54.
Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFrano C, et al. Vitamin A supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993;111(11):1456–9.
Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresan PR, Wilkening VL. Evaluation of vitamin A toxicity. Am J Clin Nutr. 1990;52(2):183–202.
Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology. 1991;100(6):1701–9.
Berson EL, Weigel-DiFranco C, Rosner B, Gaudio AR, Sandberg MA. Association of vitamin A supplementation with disease course in children with retinitis pigmentosa. JAMA Ophthalmol. 2018;136(5):490–5.
Massof RW, Finkelstein D. Supplemental vitamin A retards loss of ERG amplitude in retinitis pigmentosa. Arch Ophthalmol. 1993;111(6):751–4.
Sibulesky L, Hayes KC, Pronczuk A, Weigel-DiFranco C, Rosner B, Berson EL. Safety of <7500 RE (<25000 IU) vitamin A daily in adults with retinitis pigmentosa. Am J Clin Nutr. 1999;69(4):656–63.
Michaelsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med. 2003;348(4):287–94.
Hoffman DR, Hughbanks-Wheaton DK, Spencer R, Fish GE, Pearson NS, Wang YZ, et al. Docosahexaenoic acid slows visual field progression in X-linked retinitis pigmentosa: ancillary outcomes of the DHAX trial. Invest Ophthalmol Vis Sci. 2015;56(11):6646–53.
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Willett WC. Omega-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol. 2012;130(6):707–11.
Hughbanks-Wheaton DK, Birch DG, Fish GE, Spencer R, Pearson NS, Takacs A, et al. Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: the 4-year DHAX trial. Invest Ophthalmol Vis Sci. 2014;55(8):4958–66.
Berson EL, Rosner B, Sandberg MA, Weigel-Difranco C, Willett WC. Omega-3 intake in patients with retinitis pigmentosa receiving vitamin A-reply. JAMA Ophthalmol. 2013;131(2):267–8.
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Brockhurst RJ, Hayes KC, et al. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol. 2010;128(4):403–11.
Aleman TS, Duncan JL, Bieber ML, de Castro E, Marks DA, Gardner LM, et al. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Invest Ophthalmol Vis Sci. 2001;42(8):1873–81.
Sandberg MA, Johnson EJ, Berson EL. The relationship of macular pigment optical density to serum lutein in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2010;51(2):1086–91.
Aleman TS, Cideciyan AV, Windsor EA, Schwartz SB, Swider M, Chico JD, et al. Macular pigment and lutein supplementation in ABCA4-associated retinal degenerations. Invest Ophthalmol Vis Sci. 2007;48(3):1319–29.
Lee SY, Usui S, Zafar AB, Oveson BC, Jo YJ, Lu L, et al. N-acetylcysteine promotes long term survival of cones in a model of retinitis pigmentosa. J Cell Physiol. 2010;226:1843.
Schimel AM, Abraham L, Cox D, Sene A, Kraus C, Dace DS, et al. N-acetylcysteine amide (NACA) prevents retinal degeneration by up-regulating reduced glutathione production and reversing lipid peroxidation. Am J Pathol. 2011;178(5):2032–43.
Campochiaro PA, Iftikhar M, Hafiz G, Akhlaq A, Tsai G, Wehling D, et al. Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase 1 trial. J Clin Invest. 2019;130:1527.
Coughlan J, Manduchi R. A mobile phone wayfinding system for visually impaired users. Assist Technol Res Ser. 2009;25:849.
Hartong DT, Jorritsma FF, Neve JJ, Melis-Dankers BJ, Kooijman AC. Improved mobility and independence of night-blind people using night-vision goggles. Invest Ophthalmol Vis Sci. 2004;45(6):1725–31.
Hicks SL, Wilson I, Muhammed L, Worsfold J, Downes SM, Kennard C. A depth-based head-mounted visual display to aid navigation in partially sighted individuals. PLoS One. 2013;8(7):e67695.
Kinateder M, Gualtieri J, Dunn MJ, Jarosz W, Yang XD, Cooper EA. Using an augmented reality device as a distance-based vision aid-promise and limitations. Optom Vis Sci. 2018;95(9):727–37.
Angelopoulos AN, Ameri H, Mitra D, Humayun M. Enhanced depth navigation through augmented reality depth mapping in patients with low vision. Sci Rep. 2019;9(1):11230.
Birch DG, Locke KG, Wen Y, Locke KI, Hoffman DR, Hood DC. Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with X-linked retinitis pigmentosa. JAMA Ophthalmol. 2013;131(9):1143–50.
Cai CX, Locke KG, Ramachandran R, Birch DG, Hood DC. A comparison of progressive loss of the ellipsoid zone (EZ) band in autosomal dominant and x-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2014;55(11):7417–22.
Hariri AH, Zhang HY, Ho A, Francis P, Weleber RG, Birch DG, et al. Quantification of ellipsoid zone changes in retinitis pigmentosa using en face spectral domain-optical coherence tomography. JAMA Ophthalmol. 2016;134(6):628–35.
Jauregui R, Park KS, Duong JK, Mahajan VB, Tsang SH. Quantitative progression of retinitis pigmentosa by optical coherence tomography angiography. Sci Rep. 2018;8(1):13130.
Chiba A, Miura G, Baba T, Yamamoto S. Determination of length of Interdigitation zone by optical coherence tomography and retinal sensitivity by Microperimetry and their relationship to progression of retinitis pigmentosa. Biomed Res Int. 2019;2019:1217270.
Iftikhar M, Usmani B, Sanyal A, Kherani S, Sodhi S, Bagheri S, et al. Progression of retinitis pigmentosa on multimodal imaging: the PREP-1 study. Clin Exp Ophthalmol. 2019;47(5):605–13.
Thompson DA, Ali RR, Banin E, Branham KE, Flannery JG, Gamm DM, et al. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano symposium. Invest Ophthalmol Vis Sci. 2015;56(2):918–31.
Vazquez-Dominguez I, Garanto A, Collin RWJ. Molecular therapies for inherited retinal diseases-current standing, opportunities and challenges. Genes (Basel). 2019;10(9):654.
Sacchetti M, Mantelli F, Merlo D, Lambiase A. Systematic review of randomized clinical trials on safety and efficacy of pharmacological and nonpharmacological treatments for retinitis pigmentosa. J Ophthalmol. 2015;2015:737053.
Aleman T, Cideciyan A, Bennett J, Cheung A, Glover E, Furushima M, et al., editors. Natural history of retinal function and structure in the Rpe65−/− murine model of Leber Congenital Amaurosis: ARVO; 2003.
Aleman TS, Jacobson SG, Chico JD, Scott ML, Cheung AY, Windsor EA, et al. Impairment of the transient pupillary light reflex in Rpe65(−/−) mice and humans with Leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2004;45(4):1259–71.
Kumaran N, Michaelides M, Smith AJ, Ali RR, Bainbridge JWB. Retinal gene therapy. Br Med Bull. 2018;126:13.
Cideciyan AV, Jacobson SG. Leber congenital amaurosis (LCA): potential for improvement of vision. Invest Ophthalmol Vis Sci. 2019;60(5):1680–95.
Hauswirth WW, LaVail MM, Flannery JG, Lewin AS. Ribozyme gene therapy for autosomal dominant retinal disease. Clin Chem Lab Med. 2000;38(2):147–53.
O’Reilly M, Palfi A, Chadderton N, Millington-Ward S, Ader M, Cronin T, et al. RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet. 2007;81(1):127–35.
Sanjurjo-Soriano C, Kalatzis V. Guiding lights in genome editing for inherited retinal disorders: implications for gene and cell therapy. Neural Plast. 2018;2018:5056279.
Chalmel F, Leveillard T, Jaillard C, Lardenois A, Berdugo N, Morel E, et al. Rod-derived cone viability Factor-2 is a novel bifunctional-thioredoxin-like protein with therapeutic potential. BMC Mol Biol. 2007;8:74.
Dalkara D, Duebel J, Sahel JA. Gene therapy for the eye focus on mutation-independent approaches. Curr Opin Neurol. 2015;28(1):51–60.
Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006;103(10):3896–901.
Duebel J, Marazova K, Sahel JA. Optogenetics. Curr Opin Ophthalmol. 2015;26(3):226–32.
de Juan E, Del Cerro M, Dagnelie G, Humayun M, del Cerro C, DiLoreto D, et al. Neural retinal transplantation: a phase I clinical trial. Invest Ophthalmol Vis Sci. 1997;38(4):S261.
Humayun M, de Juan EJ, del Cerro M, Dagnelie G, Radner W, Sadda S, et al. Human neural retinal transplantation. Invest Ophthalmol Vis Sci. 2000;41:3100–6.
Ho AC, Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Handa J, et al. Long-term results from an epiretinal prosthesis to restore sight to the blind. Ophthalmology. 2015;122(8):1547–54.
Geruschat DR, Richards TP, Arditi A, da Cruz L, Dagnelie G, Dorn JD, et al. An analysis of observer-rated functional vision in patients implanted with the Argus II retinal prosthesis system at three years. Clin Exp Optom. 2016;99(3):227–32.
Haq W, Dietter J, Bolz S, Zrenner E. Feasibility study for a glutamate driven subretinal prosthesis: local subretinal application of glutamate on blind retina evoke network-mediated responses in different types of ganglion cells. J Neural Eng. 2018;15(4):045004.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Aleman, T.S. (2021). Retinitis Pigmentosa and Allied Diseases. In: Albert, D., Miller, J., Azar, D., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-319-90495-5_1-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-90495-5_1-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-90495-5
Online ISBN: 978-3-319-90495-5
eBook Packages: Springer Reference MedicineReference Module Medicine
Publish with us
Chapter history
-
Latest
Retinitis Pigmentosa and Allied Diseases- Published:
- 25 September 2021
DOI: https://doi.org/10.1007/978-3-319-90495-5_1-2
-
Original
Retinitis Pigmentosa and Allied Diseases- Published:
- 04 August 2021
DOI: https://doi.org/10.1007/978-3-319-90495-5_1-1